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Sindbis virus (SINV) (genus Alphavirus, family Togaviridae)  is  an enveloped virus
with a genome of single-stranded, positive-polarity RNA of 11.7 kilobases. SINV is
widespread in Eurasia, Africa, and Australia, but clinical infection only occurs in a
few  geographically  restricted  areas,  mainly  in  Northern  Europe.  In  Europe,
antibodies to SINV were detected from patients with fever, rash, and arthritis for
the  first  time  in  the  early  1980s  in  Finland.  It  became  evident  that  the  causative
agent of this syndrome, named Pogosta disease, was closely related to SINV. The
disease is also found in Sweden (Ockelbo disease) and in Russia (Karelian fever).
Since 1974, for unknown reason, the disease has occurred as large outbreaks every
seven  years  in  Finland.  This  study  is  to  a  large  degree  based  on  the  material
collected during the 2002 Pogosta disease outbreak in Finland.
We  first  developed  SINV  IgM  and  IgG  enzyme  immunoassays  (EIA),  based  on
highly purified SINV, to be used in serodiagnostics. The EIAs correlated well with
the hemagglutination inhibition (HI) test, and all individuals showed neutralizing
antibodies. The sensitivities of the IgM and IgG EIAs were 97.6% and 100%, and
specificities  95.2%  and  97.6%,  respectively.  E1  and  E2  envelope  glycoproteins  of
SINV were shown to be recognized by IgM and IgG in the immunoblot  early  in
infection.
We isolated SINV from five patients  with acute  Pogosta  disease;  one virus  strain
was  recovered  from  whole  blood,  and  four  other  strains  from  skin  lesions.  The
etiology of Pogosta disease was confirmed by these first Finnish SINV strains, also
representing  the  first  human  SINV  isolates  from  Europe.  Phylogenetic  analysis
indicated that the Finnish SINV strains clustered with the strains previously
isolated from mosquitoes in Sweden and Russia, and seemed to have a common
ancestor with South-African strains. Northern European SINV strains could be
maintained locally in disease-endemic regions, but the phylogenetic analysis also
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suggests  that  redistribution  of  SINV  tends  to  occur  in  a  longitudinal  direction,
possibly with migratory birds.
We  searched  for  SINV  antibodies  in  resident  grouse  (N=621),  whose  population
crashes have previously coincided with human SINV outbreaks, and in migratory
birds  (N=836).  SINV  HI  antibodies  were  found  for  the  first  time  in  birds  during
their spring migration to Northern Europe, from three individuals: red-backed
shrike, robin, and song thrush. Of the grouse, 27.4% were seropositive in 2003, one
year  after  a  human  outbreak,  but  only  1.4%  of  the  grouse  were  seropositive  in
2004. Thus, grouse might contribute to the human epidemiology of SINV.
A total of 86 patients with verified SINV infection were recruited to the study in
2002.  SINV RNA detection or  virus  isolation from blood and/or  skin lesions was
successful  in  eight  patients.  IgM  antibodies  became  detectable  within  the  first
eight days of illness, and IgG within 11 days. The acute phase of Pogosta disease
was  characterized  by  arthritis,  itching  rash,  fatigue,  mild  fever,  headache,  and
muscle pain. Half of the patients reported in self-administered questionnaires joint
symptoms to last > 12 months. Physical examination in 49 of these patients three
years after infection revealed persistent joint manifestations. Arthritis (swelling
and tenderness in physical examination) was diagnosed in 4.1% (2/49) of the
patients. Tenderness in palpation or in movement of a joint was found in 14.3% of
the patients in the rheumatologic examination, and additional 10.2% complained
persisting  arthralgia  at  the  interview.  Thus,  24.5%  of  the  patients  had  joint
manifestations attributable to the infection three years earlier. A positive IgM
antibody response persisted in 3/49 of the patients; both two patients with arthritis
were in this group. Persistent symptoms of SINV infection might have
considerable public health implications in areas with high seroprevalence.
The age-standardized seroprevalence of SINV (1999-2003, N=2529) in the human
population  in  Finland  was  5.2%.  The  seroprevalence  was  high  in  North  Karelia,
Kainuu,  and  Central  Ostrobothnia.  The  incidence  was  highest  in  North  Karelia.
Seroprevalence in men (6.0%) was significantly higher than in women (4.1%),
however, the average annualized incidence in the non-epidemic years was higher
in women than in men, possibly indicating that infected men are more frequently
asymptomatic. The seroprevalence increased with age, reaching 15.4% in persons
aged 60-69 years. The incidence was highest in persons aged 50-59 years.




Sindbis-virus kuuluu Togavirusten heimoon ja alfavirusten sukuun, ja sen
genomina on yksittäinen positiivisäikeinen n. 11,7 kiloemäksen pituinen RNA.
Sindbis-virusta esiintyy Euraasiassa, Afrikassa ja Australiassa, mutta ihmisen
oireisia infektioita lähinnä vain Pohjois-Euroopassa. Euroopassa Sindbis-
virusvasta-aineita osoitettiin nivel-ihottuma-kuumeoireisilta potilailta ensi kerran
1980-luvun alussa, Suomessa. Vasta-ainetutkimukset osoittivat, että
taudinaiheuttaja on läheistä sukua Sindbis-virukselle; tauti nimettiin
pogostantaudiksi. Ruotsissa taudin nimi on Ockelbosjuka ja Venäjällä karelskaja
lihoradka, ”karjalankuume”. Vuodesta 1974 lukien tauti on tuntemattomasta syystä
puhjennut epidemiaksi seitsemän vuoden välein. Tämä tutkimus pohjautuu
pitkälti vuoden 2002 pogostantautiepidemian aikana koottuun aineistoon.
Kehitimme laboratoriodiagnostiikkaan soveltuvat entsyymi-immunologiseen
määritykseen (EIA) perustuvat vasta-ainetestit, joilla voidaan osoittaa Sindbis-
virus-IgM- ja IgG-vasta-aineita seerumista. Menetelmien antigeenina on
puhdistettu kokoviruspreparaatti. Testien osoitettiin korreloivan hyvin
hemagglutinaation inhibitiotestin kanssa. Kaikilta testattavilta osoitettiin
neutraloivia vasta-aineita. IgM-EIA:n sensitiivisyys oli 97.6% ja spesifisyys 95.2%.
IgG-EIA:n sensitiivisyys oli 100% ja spesifisyys 97.6%. Infektion alkuvaiheen IgM-
ja IgG-vasta-aineet tunnistivat E1- ja E2-glykoproteiinit immunoblottauksessa.
Eristimme Sindbis-viruksen viidestä akuutista pogostantautipotilaasta (yksi
kokoverestä ja neljä iholeesioista), mikä varmisti Sindbis-viruksen pogostantaudin
aiheuttajaksi. Nämä ovat ensimmäiset suomalaiset Sindbis-viruskannat, ja
ensimmäiset ihmisestä eristetyt kannat Euroopassa. Fylogenia-analyysi osoitti
suomalaisten kantojen olevan läheistä sukua Ruotsissa ja Venäjällä hyttysistä
eristetyille kannoille sekä eteläafrikkalaisille kannoille. Pohjoiseurooppalaiset
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kannat saattavat kiertää paikallisesti endeemisillä alueilla, mutta virus voi myös
levitä pitkiä matkoja pohjois-eteläsuunnassa, mahdollisesti muuttolintujen avulla.
Metsäkanalintujen populaation on osoitettu romahtavan joka 6.-7. vuosi,
muistuttaen pogostantaudin epidemiasykliä. Tutkimme 621 metsäkanalintua sekä
836 muuttolintua. Sindbis-virusvasta-aineita voitiin osoittaa ensi kertaa Pohjois-
Eurooppaan saapuvista muuttolinnuista kevätmuuton aikana. Vasta-aineita
osoitettiin kolmesta yksilöstä; pikkulepinkäisestä, punarinnasta ja laulurastaasta.
Metsäkanalinnuista 27,4 % oli vasta-ainepositiivisia vuonna 2003 eli vuoden
kuluttua pogostantautiepidemiasta. Vuonna 2004 ainoastaan 1,4 % oli positiivisia.
Metsäkanalinnuilla voi siis olla rooli pogostantaudin erikoisessa epidemiologiassa.
86 serodiagnosoitua pogostantautipotilasta osallistui tutkimukseen. Sindbis-virus-
RNA:n osoittaminen tai viruseristys kokoverestä tai iholeesiosta onnistui 8
potilaasta. IgM-vasta-aineita osoitettiin viimeistään 8. ja IgG-vasta-aineita 11.
sairauspäivänä. Akuutit tyyppioireet olivat niveloireet, kutiava ihottuma,
väsymys, lievä kuume, päänsärky ja lihaskipu. Puolet potilaista ilmoitti
niveloireiden jatkuneen yli vuoden ajan. Tutkimme samat potilaat kolmen vuoden
kuluttua infektiosta havaitaksemme pitkittyneitä nivelvaivoja objektiivisesti. Tässä
vaiheessa 49 potilasta osallistui tutkimukseen. Artriitti (statuksessa turvotus ja
arkuus) todettiin 4,1 %:lla (2/49) potilaista. Palpaatio- tai liikearkuus todettiin 14,3
%:lla statuksessa. Lisäksi 10,2 % ilmoitti haastattelussa pitkittynyttä nivelkipua.
Kaikkiaan 24,5 %:lla oli niveloireita, jotka olivat ajallisesti liitettävissä
pogostantaudin alkuun ja jotka eivät selittyneet muulla sairaudella. IgM-vasta-
aineita osoitettiin 3/49 potilaista; molemmat artriitti-potilaat olivat IgM-
positiivisia. Pohjois-Karjalassa noin 10 % väestöstä on sairastanut pogostantaudin;
arvion mukaan maakunnan alueella on satoja potilaita, joiden krooninen
niveltulehdus johtuu aiemmasta Sindbis-virusinfektiosta. Pogostantaudin
mahdollisuus tulisi huomioida epäselvien niveltulehdusten erotusdiagnostiikassa.
Suomalaisten ikävakioitu Sindbis-viruksen seroprevalenssi (1999-2003, N=2529) oli
5,2 %. Seroprevalenssi oli korkea Pohjois-Karjalassa, Kainuussa ja Keski-
Pohjanmaalla. Insidenssi oli korkein Pohjois-Karjalassa. Miesten seroprevalenssi
(6,0 %) oli merkitsevästi korkeampi kuin naisten (4,1 %), mutta naisilla insidenssi
oli miehiä korkeampi. Seroprevalenssi nousi iän mukana ja se oli korkein 60-69-
vuotiailla (15,4 %). Insidenssi oli korkein 50-59-vuotiailla.
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REVIEW OF THE LITERATURE
1. ARBOVIRUSES AS HUMAN PATHOGENS
Arboviruses or arthropod-borne viruses include several hundred viruses that are
primarily transmitted by arthropods, e.g. mosquitoes, ticks, and sandflies; i.e.
arthropods function as vectors for arboviruses. These viruses are maintained in a
non-human vertebrate host, and transmission to humans or other vertebrates
occurs  through  blood  feeding  by  vectors.  Some  arboviruses  are,  in  addition,
maintained  by  a  vertical  transmission  from  the  female  adult  to  its  offspring.
Arboviruses replicate in both arthropod and vertebrate cells.
Arboviruses  that  are  pathogenic  to  humans  are  a  mixed  collection  from  five
different taxonomical families: Bunyaviridae, Flaviviridae, Reoviridae, Rhabdoviridae,
and Togaviridae (Table 1). Many of them can cause a severe human disease, such as
yellow fever, dengue, and Japanese encephalitis, which all are globally recognized
infections. The clinical diseases caused by arboviruses vary from an encephalitic
disease to hemorrhagic fever or rash-arthritis. The infection may also remain
asymptomatic or subclinical. Humans are usually dead-end hosts for arboviruses,
unable to produce significant viremia.
Human pathogenic arboviruses currently known to circulate in Finland are Inkoo
virus  (Bunyaviridae) [30], Sindbis virus (SINV) (Togaviridae) [28], and tick-borne
encephalitis virus (Flaviviridae)  [245].  Acute  Inkoo  virus  infection  is  rarely
serodiagnosed,  but  this  is  most  probably  due  to  low  clinical  alert,  and
subsequently  considerable  underdiagnosis  [201].  A  few  tens  of  tick-borne
encephalitis cases are serodiagnosed annually, mostly in the Åland islands [244].
The  number  of  acute  SINV  infections  serodiagnosed  annually  varies  from  only
few cases to over a thousand [31], and thus, in average, SINV infection is the most
commonly serodiagnosed arbovirus infection in Finland.
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2. INTRODUCTION TO ALPHAVIRUSES
CLASSIFICATION, GENOMIC STRUCTURE, AND REPLICATION
The taxonomic virus family Togaviridae consists of the genus Alphavirus and the
genus Rubivirus. The best known representative in the genus Rubivirus is rubella
virus, the causative agent of German measles. In the literature, the genus
Alphavirus has been divided into seven antigenic (sero)complexes: Barmah Forest,
eastern equine encephalitis, Middelburg, Nduma, Semliki Forest, Venezuelan
equine encephalitis, and western equine encephalitis [41].
The alphavirus virion is spherical, ~70 nm in diameter (Figure 1), and consists of a
nucleocapsid enclosed within a lipoprotein envelope [238]. The nucleocapsid and
envelope proteins are arranged in an icosahedral (T = 4) symmetry. Alphaviruses
have a linear single-stranded positive-polarity genome of 11-12-kilobase RNA,
with  a  5’-terminal  cap  structure  and  3’-poly(A)  tail,  and  which  serves  as  a
messenger RNA in mammalian cells [227].
Alphaviruses attach to the host cell via the glycoprotein spikes of the viral surface
and  enter  the  cell  by  endocytosis  in  clathrin-coated  pits  [63].  In  the  low  pH  of
endosomes, the E1/E2 heterodimers dissociate. E1 units trimerize and expose their
fusion peptides,  which drives  the fusion of  the endosomal  and viral  membranes
[142].  During the exposure to  the cytoplasm,  the nucleocapsids  disassemble.  The
infective  genome  is  released  to  the  cytoplasm.  The  5’  two-thirds  of  the  genomic
RNA  is  translated  to  produce  the  polyproteins  P123  and  P1234,  from  which  the
non-structural proteins nsP1-4 are proteolytically cleaved [205]. The P1234 is also a
precursor  for  the  RNA  polymerase.  A  subgenomic  26S  messenger  RNA,
transcribed from the terminal one-third of the genomic RNA, encodes a structural
polyprotein p130, from which the structural proteins C (capsid), 6K, and E1 (~50
kd), E2 (~45 kd), and E3 envelope glycoproteins are proteolytically cleaved
[84,122,205] (Figure 2).
The C proteins interact with each other and with viral RNA in order to assemble
into nucleocapsids. The viral membrane glycoproteins are translocated into the
lumen of endoplasmic reticulum [95]. The E3/E2-precursor (p62) and E1 are
cleaved cotranslationally in the endoplasmic reticulum by signal peptidase [143].
p62 is cleaved by furin to E2 and E3 during the exit from the trans-Golgi
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Table 1.
Arboviruses with a known human pathogenicity. Viruses with yet unestablished
pathogenicity  (e.g.  only  one  case  report)  are  not  included.  The  reference  in  which
connection to human disease was first reported is indicated. M, mosquito; T, tick, S, sandfly
Family Genus Subgroup Virus Vector Disease
Geographic
distribution Reference
Bunyaviridae Orthobunyavirus Bunyamwera Batai (Calovo) M fever Eurasia, Africa Bárdos et al . 1966
Bwamba M fever Africa Smithburn et al.  1941
Cache Valley M encephalitic
disease
North America Holden and Hess 1959
Ngari M hemorrhagic
fever
















Eurasia Oker-Blom and Brummer-
Korvenkontio 1985, Putkuri





North America Grimstad et al.  1982
La Crosse M encephalitic
disease





North America Fauvel et al . 1980
Tahyna M fever Eurasia, Africa Bárdos and Sluka 1963
Simbu Oropouche M fever,
arthralgia
South America Anderson et al . 1961
Phlebovirus Rift Valley
Fever






















Gear et al.  1982
not assigned Bhanja T fever,
myalgia
Eurasia, Africa Calisher and Goodpasture
1975















Kokobera M arthralgia Australia Doherty et al.  1964
Kunjin M encephalitic
disease





Australia Anderson et al.  1951
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North and South America Muckenfuss et al . 1933





Smithburn et al. 1940




Lopes et al. 1978
Spondweni Zika M fever Southeast Asia Moore et al . 1975 and
Olson et al. 1981
Yellow fever Yellow fever M hemorrhagic
fever
Africa, South America Stokes et al.  1928
Wesselsbron M flu-like
disease




























Europe, Russia Zilber and Soloviev 1946
Reoviridae Seadornavirus Banna M encephalitic
disease?














India Bhatt and Rodrigues 1967
Togaviridae Alphavirus Barmah Forest Barmah Forest M fever, rash,
arthritis









North, Central, and South
America
Feemster 1938, Fothergill
et al . 1938





Mayaro M fever, rash,
arthritis
South America Anderson et al . 1957
O'nyong-nyong M fever, rash,
arthritis
Africa Williams et al.  1965
Ross River M fever, rash,
arthritis
Oceania Doherty et al.  1972
Semliki Forest M fever Africa Willems et al.  1979,
















Sindbis M fever, rash,
arthritis
Eurasia, Australia, Africa Malherbe et al . 1963,






North, Central, and South
America
Howitt 1938
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network  [214].  p62  and  E1  are  assembled  as  heterodimers  in  the  endoplasmic
reticulum.  E3  is  cleaved  in  the  Golgi.  E1-E2  heterodimers  are  transported  to  the
plasma membrane, and form trimeric viral spikes. The virus matures by budding
at the plasma membrane, from which the virus membrane is derived from [4].
Figure 1.
Electron microscopy image of purified SINV.
Alphaviruses can cause cytopathic effect (CPE) in various mammalian and insect
cells,  and  can  be  easily  propagated  into  high  titers,  in  temperatures  up  to  41°C
[238], or even as low as 5°C [247]. CPE is characterized by cell rounding,
degeneration, lysis, and eventually complete destruction of cell monolayers [238].
Alphavirus infection of vertebrate cells results in inhibition of host protein
synthesis, which begins at approximately three hours after infection [228].
Peculiarly,  evidence  suggests  that  the  transcriptional  shutoff  caused  by  the  Old
World alphaviruses depends on nsP2, whereas C protein determines this
phenomenon with the New World alphaviruses [94].
PHYLOGENETIC RELATIONSHIPS AND GEOGRAPHIC DISTRIBUTION
The phylogenetic relationships of alphaviruses, based on the glycoprotein genes
(Figure 3), resemble those of the suggested serocomplex division [41]. In addition,
different  alphaviruses  are  clustered  in  many  respects  according  to  the  diseases
they cause in humans (Figure 3). The origin of alphaviruses is probably in the
New World (the Americas) [238]. The general assumption is that Venezuelan
equine encephalitis virus (VEEV) diverged from eastern equine encephalitis virus
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(EEEV) 1,000 to  2,000 years  ago,  and SINV and SFV were later  introduced to  the
Old World [250]. A recent report, however, suggests the contrary: alphaviruses
may have an Old World origin, instead [137]. Recombination of SINV- and EEEV-
like viruses produced western equine encephalitis virus (WEEV) [105].
Currently,  WEEV,  EEEV,  VEEV,  and Mayaro virus  (MAYV) are  exclusively found
in the New World,  Barmah Forest  (BFV) and Ross  River  virus  (RRV) in  Oceania,
and O’nyong-nyong virus (ONNV) and SFV in Africa. In addition, antibodies to a
SFV complex virus have been reported in both birds and humans in Europe, but
circulation of such viruses is not established in this continent [152]. Chikungunya
virus  (CHIKV)  infections  have  been  reported  in  Southeast  Asia  and  Africa,  and
most recently on the Indian Ocean islands where a massive outbreak began at the
end of 2004 [75]. SINV, circulating in Eurasia, Australia, and Africa, is the only
human pathogenic alphavirus indigenous in Europe. Interestingly, SINV isolates
from Northern Europe and from South Africa are closely related [187], suggesting
possible involvement of migratory birds in the distribution of the virus.
Figure 2.
Genomic organization of alphavirus.
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Figure 3.
Phylogenetic relationships of alphaviruses within the E1 region. The viruses and subtypes
known to cause disease in humans are highlighted. Black boxes, arthritogenic disease;
white boxes, neuropathogenic disease. Phylogenetic tree is based on the nucleotide
sequences from E1 region, nucleotides 10,338-11,337; the genome position is given
according to the published sequence of the strain AR339 (HRsp variant). The tree was
constructed by using neighbor-joining algorithms (NEIGHBOR); 1,000 bootstrap replicates
were calculated. Phylogenetic analysis by courtesy of Dr. Tarja Sironen. The following
sequences available in GenBank were included in the comparison:
SDV, sleeping disease virus, subtype unknown, France (AJ238578)
SPDV, salmon pancreas disease virus, F93125, United Kingdom (AJ012631)
BFV, Barmah Forest virus, BH2193, Australia (U73745)
ONNV, O’nyong-nyong virus, Gulu, Uganda (M20303)
CHIKV, Chikungunya virus, Ross, Tanganyika (East Africa) (AF192905)
NDUV, Ndumu virus, SAAr221D, South Africa (AF398375)
MAYV, Mayaro virus, TRVL4675, Trinidad (AF398378)
MIDV, Middelburg virus, SA AR749, South Africa (AF398374)
RRV, Ross River virus, T48, Australia (M20162)
BEBV, Bebaru virus, MM2354, Malaysia (AF398376)
GETV, Getah virus, MM2021, Malaysia (AF398377)
SFV, Semliki Forest virus, subtype and origin unknown (X04129)
SFV (Me Tri), Semliki Forest virus, Me Tri, Vietnam (AF398380)
TROCV, Trocara virus, BeAr422431, Brazil (AF252264)
AURAV, Aura virus, BeAr10315, Brazil (AF126284)
WHATV, Whataroa virus, M78, New Zealand (AF398394)
SINV (Kyzylagach), Kyzylagach strain, Leiv65A, Azerbaijan (AF398392)
SINV (AR339, HRsp variant), Sindbis virus, AR339, Egypt (J02363, J02364, J02365, J02366, J02367)
SINV (Babanki), Babanki strain, DAK ArY251, Cameroon (AF398391)
SINV (Ockelbo), Ockelbo strain, Edsbyn 82-5, Sweden (M69205)
FMV (Buggy Creek), 81V1822, Oklahoma (AF398390)
FMV, Fort Morgan virus, 73V1570, Colorado (AF398389)
HJV, Highlands J virus, 64A-1519, Florida (U52586)
WEEV (California), western equine encephalitis virus, BFS1703, California (J03854)
WEEV (Argentina), ag80-646, Argentina (AF398393)
EEEV-I, eastern equine encephalitis virus, lineage 1, 82V2137, Florida (U01034)
EEEV-IV, lineage 4, 430687, Brazil (AF159561)
EEEV-III, lineage 3, 435731, Panama (AF159560)
EEEV-II, lineage 2, BeAn5122, Brazil (AF159559)
VEEV-V (Cabassou), subtype V, CaAr508, French Guiana (AF398387)
VEEV-IIIC, subtype IIIC, 71D1252, Peru (AF398386)
VEEV-IIIA (Mucambo), subtype IIIA, BeAn8, Brazil (AF398383)
VEEV-IIIB (Mucambo, Tonate), subtype IIIB, CaAn410d, French Guiana (AF398384)
VEEV-IIIB (Mucambo, Bijou Bridge), subtype IIIB, Bijou Bridge, Colorado (AF398385)
VEEV-IF, subtype IF, 78V3531, Brazil (AF398382)
VEEV-VI, subtype VI, Ag80-663V, Argentina (AF398388)
VEEV-IV (Pixuna), subtype IV, BeAr35645, Brazil (AF075256)
VEEV-IE, subtype IE, 68U201, Guatemala (U34999)
VEEV-II (Everglades), subtype II, Fe3-7c, Florida (AF075251)
VEEV-ID, subtype ID, 3883, Panama (L00930)
VEEV-IAB, Venezuelan equine encephalitis virus, subtype IAB, Trinidad donkey, Trinidad (L01442)
VEEV-IC, subtype IC, P676, Venezuela (L04653)
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RESERVOIRS AND VECTORS
Mosquitoes  are  the  primary  vectors  for  all  alphaviruses,  and  various  vertebrate
hosts function as their reservoir hosts, depending on the virus and geography.
The hypothesis is that SINV cycles between ornithophilic mosquito species and
birds; a cycle resembling e.g. that of West Nile virus. Culex [126,167] and Culiseta
[181] mosquitoes are considered the primary vectors for SINV. Birds might be
involved in the natural cycle of SINV as important reservoirs [88,153,169], but
spillover to other vertebrates may occur, as well. Culex annulirostris and
Ochlerotatus vigilax are  evidently  the  most  important  vectors  for  RRV  [87].  The
reservoir host for RRV is unknown; however, marsupials and birds may play an
important role [111]. Aedes species  are  probably  important  vectors  for  BFV
[211,248], but its reservoir remains unestablished. ONNV is transmitted by
Anopheles mosquitoes [254]; the search for its reservoir host has repeatedly failed
[189]. The principal vector for CHIKV is Aedes aegypti, but during the recent
outbreak on the Indian Ocean islands, Aedes albopictus,  which  is  usually
considered to have a low vectorial competence in vivo, was also involved [204].
Monkeys,  rodents,  birds  are  the  suggested  hosts  for  CHIKV  [197]. Haemagogus
janthinomys mosquitoes  are  probably  the  principal  vectors,  and  marmosets
(monkeys) the main amplifying hosts for MAYV [116].
WEEV transmission cycle involves Culex tarsalis as the primary vector and house
finches and house sparrows as the primary amplifying hosts, and to a lesser extent
other passerine species, chickens, and possibly pheasants. WEEV also cycles
between Aedes melanimon and the blacktail jackrabbit [109].
Spiny  [42]  and  cotton  [260]  rats  are  the  suggested  primary  hosts  for  VEEV.  It  is
evident  that  an  epizootic  in  equines  usually  precedes  human  VEEV  epidemics.
During the epidemics, several mosquito species, including Psorophora confinnis, P.
columbiae, Ochlerotatus sollicitans, O. taeniorhynchus, and different Culex species, can
function as  vectors  for  the virus  [249],  whereas  the enzootic  vectors  of  VEEV are
all members of the Culex melanoconion subgenus [82].
The North American and South American EEEV transmission cycles differ from
each  other.  The  majority  of  mosquito  isolations  of  EEEV  in  North  America  have
been from Culiseta melanura with several studies demonstrating either neutralizing
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antibodies  or  the  virus  from  passerines  [217].  Thus,  EEEV  is  considered  to  cycle
between Culiseta melanura and  passerine  birds  in  North  America.  The  virus  has
also been isolated from Aedes albopictus [172], which is a cause for concern, since
the species is widely spread in the US. In South America, the EEEV transmission
cycle  is  not  established in  detail.  However,  mosquitoes  in  the Culex melanoconion
subgenus are probably involved in the transmission, and rodents and marsupials
might function as vertebrate hosts for the virus [217].
ALPHAVIRUSES AS HUMAN PATHOGENS
Human pathogenic alphaviruses cause either an arthropathic disease (BFV,
CHIKV, MAYV, ONNV, RRV, SINV) or a neuropathogenic (encephalitic) disease
(EEEV, VEEV, WEEV) (Figure 3).  In  addition,  SFV  can  cause  a  fever  syndrome,
sometimes including arthralgia, reported in a single natural epidemic [166], and as
a fatal laboratory-acquired infection [253]. Neuropathogenic alphaviruses are
considered potential agents for bioterrorism [68]. Human pathogenicity of SINV
and  SFV  is  noteworthy,  since  they  are  widely  used  as  models  in  virus  research,
and considered potential tools for gene therapy [156].
RRV is the most commonly reported alphavirus infection on a regular basis, with
approximately 1,500-8,500 cases per year in Australia (1993-2006) [3]. The annual
number of BFV cases in Australia has been roughly 1,000 [3]. Clinical SINV
infection is almost exclusively found in Northern Europe, with a few tens to over
1,300 cases per year in Finland [2]. For unknown reason, SINV outbreaks have
peculiarly occurred every seven years in Northern Europe since 1974 [31]. The last
outbreak took place in 2002 [2].
Millions of people manifested with ONNV infection in Uganda in the 1950s [255],
and the virus re-emerged there in the 1990s [209]. Sporadic CHIKV outbreaks
were reported in Africa and Southeast Asia before the massive outbreak in Indian
Ocean with several hundred thousand people infected in 2004-2006 [75]. Several
small MAYV outbreaks have occurred in South America [43,199,234].
In the US, 0-21 cases of EEEV and 0-172 cases of WEEV were reported per year
during 1964-2005 [1]. VEEV has occurred in the Americas as periodic outbreaks,
and one of the largest VEEV epidemics involved an estimated 75,000 to 100,000
people in 1995 in Venezuela [251].
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In conclusion, many of the human pathogenic alphavirus infections tend to have a
fluctuating incidence with occasional, sometimes massive, outbreaks followed by
years of silence. RNA viruses have very high mutation rates. Virus-encoded RNA-
dependent  RNA  polymerase,  which  is  responsible  for  genome  replication  in
positive-stranded RNA viruses, has no proof-reading activity. These aspects enable
alphaviruses  to  transform  from  endemic  virus  strains  to  epidemic  strains,  and
facilitate their adaptation to hosts and vectors.
3. CLINICAL REVIEW OF NEUROPATHOGENIC ALPHAVIRUSES
Neuropathogenic alphavirus infections with an established association with
clinical disease are reviewed below. All these viruses are major equine pathogens,
but occasionally equine epizootics expand to human epidemics.
EASTERN EQUINE ENCEPHALITIS VIRUS
EEEV infections are reported in the eastern and southern parts of the US [1]. Since
the first outbreak in 1831 in Massachusetts [108], infections in horses consistent
with  the  clinical  picture  of  EEEV  infection  were  reported  in  several  instances  in
North  America.  The  human  EEEV  outbreak  in  the  summer  of  1938  in
Massachusetts  was  the  first  time  any  equine  virus  has  verifiably  caused  a
symptomatic infection in humans [79,85,98]. Thus far, the Massachusetts outbreak,
and the one in New Jersey in 1959 [99], have been the most prominent EEEV
outbreaks  in  humans  with  several  tens  of  cases  diagnosed  in  laboratory.  Even
though the disease is rare, EEEV infection is clinically important due to its high
mortality  and  severe  symptoms.  The  clinical  course  of  symptomatic  EEEV
infection is the most severe of the three equine encephalitides. Comparison  of the
pathogenesis of EEEV and WEEV in mice has shown that although both are highly
neurotropic, EEEV is far more virulent [150].
With North American EEEV strains it has been demonstrated that 3-6% of infected
humans are symptomatic [100]. A symptomatic EEEV infection typically manifests
with high fever, headache, nausea and vomiting, malaise, stupor, convulsions,
meningeal irritation (neck stiffness) and nonfocal weakness [62,80,98,112]. In
addition, confusion, myalgia, arthralgia, signs of dysfunction in upper (positive
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Babinski sign) or lower (focal weakness) motor neurons, chills, and seizures are
common [62]. Infants sometimes present with a peculiar edema around the eyes
and in the upper extremities [80].
In fatal cases, the duration of the acute illness is usually less than one week; in the
survivors the duration is usually several weeks [98]. Children are most often
affected by clinical EEEV infection [98]. Serious or fatal symptoms caused by
EEEV infection are most often seen in small children [80]. The onset of symptoms
is typically more sudden in infants than in older patients [80,98].
At the early stage of the disease, cerebrospinal fluid (CSF) shows pleocytosis, and
an elevated protein concentration and red-cell count in most cases [62]. In
peripheral blood, leukocytosis and hyponatremia are typical [62].
Electroencephalography typically shows generalized slowing and disorganization
of the background [62]. In neuroradiologic examinations abnormal findings are
often seen, especially in the areas of basal ganglia and thalami [62,157,198].
Evidence suggests that high white-cell count in CSF and severe hyponatremia at
the early stages of the disease can be a sign of poor prognosis [62].
Long-term, sometimes even fatal, sequelae are common in patients who survive
the acute phase of the EEEV infection [12,98]. There are various long-term effects,
such  as  mental  retardation  or  deficiency,  lack  of  emotional  control,  aphasia,
paresis, cranial nerve palsies, deafness, recurrent convulsions, or epilepsy, which
all  can  continue  for  years  or  become  permanent  [12].  Of  the  eight  patients  that
were followed for nine years after the outbreak in Massachusetts in 1938, two died
and only one had a complete recovery [12], reflecting the poor long-term
prognosis of the infection. Nine years after this outbreak the overall mortality rate
was 90% in the 34 patients reported [12]. The mortality among the 36 patients who
had acquired EEEV infection during 1988-1994 in the US was 36%; in addition,
35% manifested with moderate or severe disability [62].
WESTERN EQUINE ENCEPHALITIS VIRUS
WEEV  was  first  isolated  from Culex tarsalis mosquitoes in Yakima Valley in the
North-Western US in 1941 [107]. Human WEEV infections are exclusively reported
in the Western Hemisphere, and most infections occur in the western and central
US states [1].
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Generally, acute WEEV infection is characterized by fever, headache, drowsiness,
signs of meningeal irritation (neck stiffness), nausea, vomiting, muscle aches, and
more rarely, paresis and convulsions [139]. In infants, in contrast, convulsions are
common, and the progression of the disease more rapid [48,74]. During the acute
phase, white blood cell count is normal or slightly elevated in peripheral blood;
CSF glucose level is normal, whereas protein level and white blood cell count can
be elevated [139]. Lateralized abnormalities in the electroencephalogram are
possible, but not typical [230].
After the encephalitic symptoms have subsided, some patients manifest with
Parkinson-like symptoms [177,216]. Other long-term sequelae vary from difficulty
in coordination and speech to muscle rigidity and cognitive impairment [177].
Psychiatric sequelae are possible [93]. Even intracranial calcifications have been
described in a pediatric case five months after the infection [225].
The severity of the sequelae is possibly related to the duration of unconsciousness
at  the acute  phase [177].  The detected antibody response and the severity  of  the
acute illness do not seem to correlate [48]. The mortality rate of WEEV infection is
significantly lower than in EEEV infection, approximately 3-5% [35,74]. The ratio
of subclinical to clinical infections ranges from 50:1 in children to 1000:1 in adults
[74]. Transplacental transmission of WEEV can occur [52,220].
VENEZUELAN EQUINE ENCEPHALITIS VIRUS
VEEV  is  present  in  Central  America,  and  northern  and  eastern  parts  of  South
America [249]. Epidemics and equine enzootics occur periodically, sometimes in a
massive scale [251]. VEEV subtypes IA-C that have the potential to cause an
epizootic, cause more severe, and highly fatal infection in equines than the
enzootic subtypes (ID-F, II-VI). However, the severity of the human disease does
not  necessarily  depend  on  the  subtype,  and  is  often  self-limited.  A  recent  study
provides evidence that only a few site mutations in the E2 region can cause
transformation of the VEEV from an enzootic to an epidemic strain [9]. In addition
to its innate neurovirulence, the potential of a VEEV strain to cause encephalitis
seems to be related to its ability to replicate extra-cerebrally [249].
The onset of the acute disease is usually sudden, but the clinical course may vary
considerably. Most of the patients manifest with an influenza-like infection, with a
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few  days  of  fever,  pharyngitis,  and  general  symptoms,  whereas  some  infections
are much more severe, either characterized by convulsions, shock, and coma or an
encephalitic form of illness with central nervous system manifestations [72]. In
general, most patients feature fever, headache, muscle pain, and nausea or
vomiting [60,64,132]. Signs of meningeal irritation (neck stiffness) or focal
neurologic manifestations are not seen in most patients [64]; neurologic disease
appears in <15% of the serodiagnosed cases [249]. Similar to EEEV and WEEV,
children manifest with a more severe form of illness than adults, and their fatality
rate  is  higher  [72].  Lymphopenia  in  the  peripheral  blood  is  typical  for  the  acute
phase [64].
In the less severe cases, defervescence takes place rapidly, within a few days [64],
and other symptoms usually subside within a week [249]. However, recurrence of
symptoms, particularly fever and headache, can occur [72,132]. Sequelae of a
severe VEEV infection can include various neurologic deficits [140]. VEEV can
vertically infect a fetus, resulting in stillbirth, spontaneous abortion or a severe
neurologic infection of the infant [252].
PATHOGENESIS OF NEUROPATHOGENIC ALPHAVIRUS INFECTIONS
Various histopathologic changes take place in brain tissue during EEEV infection.
Polymorphonuclear and mononuclear cells accumulate in perivascular and
meningeal regions and neuron destruction occurs [80,112,123,256]. Small thrombi
are seen in vessels [80]. In addition to brain tissue, EEEV infects various organs in
a  hamster  model,  including  heart,  lung,  liver,  kidney,  and  spleen  [193].  In  a
hamster model, brains show considerable hyperemia, vasculitis, and
subependymal and subarachnoidal hemorrhages [193]. Small thrombi have also
been  reported  to  form  in  internal  organs  [80].  Studies  with  mice  have
demonstrated that EEEV replication takes place in metaphyseal osteoblasts at the
early stage of the infection, possibly explaining the vulnerability of the young to
the more severe infection [243]. Perivascular infiltration and multifocal necrosis,
especially in the deep grey matter of the brain [5], as well as edema and meningeal
lesions [35] are seen in fatal WEEV cases.
Studying fatal cases of VEEV infection has revealed that histopathologic lesions,
especially edema, congestions, and meningitis, are seen in the central nervous
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system without exception [59]. Histopathologic lesions in other organs typically
involve follicular necrosis in the spleen and lymph nodes, congestion/edema and
interstitial pneumonia in the lungs, hepatocellular degeneration in the liver, and
lymphoid follicle necrosis, congestion, and edema in the gastrointestinal tract [59].
Destruction  of  lymphocytes,  especially  in  the  young,  is  considered  to  play  an
important  role  in  the  pathogenesis  of  VEEV  infection  [72].  A  mouse  model  has
shown that after the infection, and subsequent clearance of VEEV from the visceral
organs, the virus begins to appear in the brain, first in the olfactory tracts [58]. The
E2 glycoprotein appears to play an important role in the pathogenesis of VEEV at
a very early step, by rendering its spread to the draining lymph node and beyond
[10,58,162]. After subcutaneous inoculation of mice, VEEV replication takes place
in the lymph node draining [10,162]. It is notable that SINV and SFV, which cause
an arthropathic disease in humans, are neuropathogenic in mice in an age-
dependent manner [78,121].
4. CLINICAL REVIEW OF ARTHRITOGENIC ALPHAVIRUSES
Arthritogenic alphavirus infections with an established association with clinical
disease  are  reviewed  below.  Except  for  BFV  and  SINV,  all  arthritogenic
alphaviruses are members of the SFV serocomplex. SFV infection is not reviewed
here due to its rarity and poorly described clinical manifestations [166,253].
SINDBIS VIRUS
SINV  was  first  isolated  in  1952  from  a  pool  of Culex pipiens and C. univittatus
mosquitoes collected from the village of Sindbis in the Nile river delta in Egypt
[232]. The first human isolations took place in Uganda in 1961, but possible clinical
manifestations of the individuals were not reported [257]. The virus was recovered
for  the first  time from an acutely  ill  patient  in  South Africa  (Girdwood strain)  in
1963 from the vesicle fluid of skin lesions [164]. The virus was associated as the
causative agent of a rash-arthritis syndrome [168].
In  Europe,  antibodies  to  SINV were found for  the first  time by screening human
sera in 1965 in Finland [29], but a connection to a clinical disease remained to be
shown.  In  the  late  summer  of  1974,  in  the  Eastern  Finland  village,  Ilomantsi,  a
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general physician noticed a peculiar rash and simultaneous joint pain in several
patients  within  a  few  months  time.  The  syndrome  was  named  Pogosta  disease,
according to the name of the village. Pogosta disease was serologically associated
with SINV infection in 1980 [28].
SINV or antibodies to SINV are widely found in insects and vertebrates in Eurasia,
Africa, and Oceania. However, clinical disease caused by SINV infection is almost
exclusively reported in  Northern Europe,  with only sporadic  cases  elsewhere.  In
Northern Europe, the virus has a peculiar epidemiologic cycle: since 1974 an
epidemic has occurred every seven years, latest in 2002 [31] (Figure 4). The largest
outbreak  thus  far  in  Finland  took  place  in  1995,  with  over  1,300  serodiagnosed
cases [2]. Similar disease is also found in Sweden (Ockelbo disease) and Russian
Karelia (Karelian fever); SINV has been isolated from mosquitoes in both
[160,181]. In Sweden, the number of cases has been considerably lower. For
example,  during  the  2002  epidemic  in  Finland,  with  approximately  600
serodiagnoses, only four patients were serodiagnosed in Sweden (Sirkka Vene, the
Swedish Institute  for  Infectious Disease Control,  personal  communication).  From
Russia, the number of SINV infections is not available, but it is plausible that the
endemic  zone  in  Eastern  Finland  must  continue  over  to  the  Russian  side  of  the
border.
Figure 4.
Annual number of serodiagnosed Pogosta disease cases during 1981-1996. Data from
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Brummer-Korvenkontio et al. have  previously  screened  SINV  antibodies  in
Finland [31]. The incidence of SINV in 1980-1996 was 2.7/100,000 in Finland, with
the highest incidence in the provinces of North Karelia and Central Finland. The
seroprevalence in over 600 individuals without joint manifestations in Ilomantsi,
North Karelia, Eastern Finland in 1982 was 39%, being considerably higher than in
1980, due to the disease epidemic in 1981. The seroprevalence in 5000 pregnant
women in their first trimester in February 1992 throughout the country was 0.6%.
17% of game mammals (N=41) and 30% of birds (N=80) were positive in SINV
antibody testing in Ilomantsi during 1981-1983.
Maculopapular (itchy) skin rash, fever, and joint symptoms, particularly in wrists,
hips,  knees,  and  ankles,  are  the  hallmarks  of  the  acute  clinical  picture  of  SINV
infection, sometimes accompanied by nausea, general malaise, headache, and
muscle pain [76,239,242]. Infectious parameters are typically normal [239]. There is
one case report of cutaneous hemorrhagic vesicles during the acute phase of SINV
infection [103].
Evidence suggests that SINV infection can cause prolonged joint manifestations.
In a questionnaire study and telephone interview carried out with Ockelbo disease
patients in 1985 in Sweden, 24% (21/86) of the patients reported arthralgia three to
four  years  after  infection,  and  the  symptoms  had  a  temporal  linkage  with  the
infection. Of the 21 patients 14 complained arthralgia 5-6 years after infection, and
the symptoms mostly affected hands and feet; arthralgia was present often in the
same joints that manifested with most severe symptoms at the acute phase
[180,182]. In a smaller study in 1989, 31% (5/16) of the patients with Ockelbo
disease complained joint ache when interviewed by telephone 2.5 years after
infection [242]. Chronic arthritis and Pogosta disease were linked in a case report
in 2000 [158], and a clinical examination of 26 patients 2.5 years after serologically
confirmed SINV infection showed that 8% (2/26) of the patients had arthritis, and
42% (11/26) had either osteoarthritis, fibromyalgia or occasional arthralgia [133].
ROSS RIVER VIRUS
RRV is present exclusively in Oceania, where the first human outbreak took place
in the 1920s, in South-Eastern Australia [184]. The association between RRV and
the  disease  was  shown  much  later  with  serology  [67],  and  eventually  by  virus
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isolation [65]. The virus is endemic in the coastal regions of Australia, particularly
in the north-eastern parts of the country [163]. The infection is also known as
“epidemic polyarthritis”.
RRV disease is found in all age groups, but most commonly in the age group 30-49
years [50]. Patients with acute RRV infection present with joint symptoms, fatigue,
lethargy, muscle pain, skin rash, fever, and headache [50,83,218]. Knees, wrists,
ankles, and fingers are most commonly affected [50,110,178]. A single case of acute
glomerulonephritis during the acute phase of RRV infection has been described
[91], as well as another case of reactive arthritis and vasculitis as a consequence of
the infection [81].
Prolonged  joint  sequelae  are  seen  after  RRV  infection.  In  a  self-administered
questionnaire study, 57% of the of 255 RRV disease patients infected in 1988-89
reported joint pain at 24-42 months post infection [50], whereas in another study
in 1992-93, 12% (51/436) of the patients complained joint pain and 3% (14/436)
swollen joints 15 months after infection [218]. In a prospective clinical follow-up in
1998, 68% (32/47) of the patients complained joint pain 2.3–6.5 months after
infection [110]. In a quality-of-life questionnaire study with 67 RRV disease
patients in 1997-2000, patients with persistent symptoms usually had other
rheumatic conditions as well, suggesting that previous reports might have
overestimated the frequency of persistent joint symptoms [178].
BARMAH FOREST VIRUS
BFV was first isolated in 1974 from Culex annulirostris at Barmah Forest in South-
Eastern Australia [165]. BFV was later isolated from acutely ill patients [196]. The
virus  is  endemic  in  northern  and  north-eastern  Australia,  and  parts  of  western
Australia [83].
Maculopapular rash, joint pain, myalgia, fatigue, lethargy, fever characterize acute
BFV infection, often accompanied by headache [146,163,196]. The most commonly
affected joints are knee, ankle, wrist, fingers, hip, shoulder, and neck [17]. Similar
to RRV infection, a single case of glomerulonephritis after BFV infection has been
reported [127].
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In a self-administered retrospective questionnaire survey of 53 patients in 1995 in
Australia, arthralgia or other symptoms of BFV disease were found to last longer
than six months in half of the patients [17], but more recent data evidently suggest
that in fact only 10% of BFV disease patients feature persisting arthralgia [83].
CHIKUNGUNYA VIRUS
CHIKV  has  recently  drawn  attention  due  to  the  massive  outbreak  that  began  at
the end of 2004, involving several million people on the Indian Ocean islands, and
parts  of  India  [75].  For  instance,  an estimated 1/4-1/3  of  the residents  of  Réunion
Island,  to  where  the  virus  was  now  introduced  for  the  first  time,  acquired  the
infection during the outbreak. The outbreak also resulted in an epidemic of a few
hundred patients in Northern Italy in 2007, to where the virus was probably
introduced by a  visitor  from India,  and then transmitted to  inhabitants  by Aedes
Albopictus mosquitoes. Prior to the Indian Ocean outbreak, several smaller CHIKV
epidemics have occurred in Africa and  especially in Southeast Asia. The primary
differential diagnostic alternative of CHIKV infection is dengue virus infection;
they partially share the same geographical distribution, and their clinical pictures
resemble each other in many respects [183].
The  clinical  picture  of  the  acute  phase  of  CHIKV  infection  consists  of  fever,
agonizing arthralgia, myalgia, macular or maculopapular skin rash, and
sometimes nausea, conjunctivitis, and headache [61,183,231]. Of the joints, wrists,
ankles, and phalangeal joints are often affected [231]. In some patients,
leukopenia, thrombocytopenia, or elevated aminotransferase levels can be
observed at the acute phase [231]. Various ocular manifestations can occur [135].
Acute myocarditis has been described in a case report [171]. In general, the
symptoms of  CHIKV infection are  the same as  in  SINV infection,  but  in  a  much
more severe scale; even fatal cases have been reported [44].
In the examination of 20 South-African patients with Chikungunya fever 4-16
months after infection in 1976, 60% had at least moderate pain in joints, and 70%
(14/20) at least moderate morning stiffness [128], whereas in another study in 1977,
18% (5/28) patients manifested with arthritis 20 months after CHIKV infection [86].
A single case report has shown a possible linkage between CHIKV and destructive
arthropathy of metatarsophalangeal joints a few years after infection [24].
– REVIEW OF THE LITERATURE –
SINDBIS VIRUS AND POGOSTA DISEASE IN FINLAND 31
Serological  evidence  suggests  that  CHIKV  infection  might  be  a  risk  factor  for
Burkitt’s lymphoma [240].
O’NYONG-NYONG VIRUS
The clinical disease caused by ONNV was first described in Uganda during a
massive outbreak with an estimated two million patients in 1959-1961. During the
outbreak,  the  virus  was  isolated  from  both  acutely  ill  patients  and Anopheles
mosquitoes [254,255]. Peculiarly, the virus disappeared for 35 years to re-emerge in
1996, again in Uganda [210]. The ONNV strains isolated during these two
epidemics were closely related [136]. In addition, an ONNV outbreak occurred in
2003 in a refugee camp in Ivory Coast [199], and a single case was reported from
Chad in 2004 [19].
Acute ONNV infection has a sudden onset with slightly elevated temperature,
joint  pain,  muscle  pain,  headache,  itchy  skin  rash,  and  sometimes
lymphadenopathy and retro-orbital pain [131,221]. Knees, elbows, wrists, fingers,
and ankles are typically affected [131,221]. Severity of joint manifestations varies
from vague to excruciating [221].
Possible persistence of joint manifestations in ONNV infection is poorly known.
Shore reported that joint symptoms “caused the disease to be protracted in some
patients”  during  the  first  ONNV  outbreak  [221].  In  a  retrospective  study  three
months after the infection, the median duration of joint pain was 7 days (range, 1–
90 days) [131].
MAYARO VIRUS
MAYV, present in South America, is the only arthritogenic alphavirus in the New
World. The virus was first isolated in Trinidad in 1954 from febrile patients [6]. In
the 1950s, MAYV outbreaks were described also in the state of Pará in Brazil [43]
and in Bolivia [215]. Thereafter, small sporadic epidemics have been reported
every  now  and  then.  Although  widespread  in  South  America,  human  MAYV
infection usually occurs only in rural conditions.
Patients with acute MAYV infection present with fever, (sometimes severe) joint
pain, headache, chills, dizziness, myalgia, maculopapular skin rash, eye pain, and
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lymphadenopathy [6,43,199,234]. The onset of the disease is usually abrupt, and
wrists, fingers, ankles, and toes are commonly affected [199]. Leukopenia is typical
at the acute phase [199].
A few case reports have linked Mayaro fever with recurrent [233] and persisting
[234] arthralgia.
PATHOGENESIS OF ALPHAVIRUS ARTHRITIS
Pathogenesis of joint manifestations in the arthritogenic alphavirus infections is
inadequately understood, but several mechanisms have been suggested. SINV
replication has been detected within connective tissue adjacent to articular joints
in a mouse model [114], and RRV can be propagated in human synovial cells in
vitro [124]. Circulating immune complexes have been detected in the sera of SINV-
infected patients [125]; however, studies with RRV have shown contrary evidence
[90].
Linn and coworkers have shown that RRV persists in synovial macrophages [147],
and  later  demonstrated  this  also  with  SINV  and  other  alphaviruses  [229].  Their
further studies support the idea that persisting joint symptoms in certain
individuals could be due to inability to produce adequate anti-alphavirus
cytotoxic T lymphocyte activity [149]. On the other hand, viral tropism might play
an  important  role,  since  mouse  models  have  shown  that  the  primary  targets  of
RRV  are  musculoskeletal  tissues  [175].  Interestingly,  evidence  suggests  that  RRV
uses the collagen IV binding 1 integrin 1, as a receptor in mammalian cells;
the  collagen  receptors  and  their  genetic  variation  might  be  related  to  the
pathogenesis  [148].  As  for  genetic  determinants,  evidence  suggests  that  human
leukocyte antigen haplotype DR7 is more prevalent among RRV patients [92]. A
recent study indicates that complement activation occurs in response to RRV
infection and enhances the severity of the disease in mice [174].
In  a  recent  study  on  patients  with  CHIKV  infection,  CHIKV  antigen  could  be
detected by immunohistochemistry in muscle satellite cells, which are myogenic
precursor cells considered the main cell type responsible for postnatal muscle
growth and repair [192]. Notably, CHIKV antigen could not be detected in muscle
fibers, infiltrating cells, or endothelial cells [192].
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5. ALPHAVIRUS DIAGNOSTICS, TREATMENT, AND PREVENTION
The laboratory diagnosis of all alphavirus infections is primarily based on
serology,  i.e.  detection  of  specific  IgM  antibodies  and/or  seroconversion  of  IgG
between paired samples. The possible serological methods include EIAs,
hemagglutination inhibition (HI) test, neutralization tests (NT), and immunoblot
[22,36,47,120,179,207,242]. Various PCR techniques [118] and virus isolation can
also be used. However, the viremic window in alphavirus disease is usually brief,
which can limit their routine use. A special reverse transcriptase polymerase chain
reaction (RT-PCR)-EIA technique, which is able to distinguish between EEEV,
WEEV, and VEEV, has also been described [246].
No specific antiviral treatment is available for any of the alphavirus infections.
Thus,  patients  are  only  treated  symptomatically.  The  treatment  of
neuropathogenic infections focuses on supporting vital functions, and on
anticonvulsion. Symptoms of arthritogenic infections can be relieved with non-
steroidal anti-inflammatory agents, and rash with antihistamins. In vitro studies
provide potential for the drug development in the future. A recent study on mice
provided  evidence  that  certain  form  of  steroids  (seco-pregnane steroids) have a
potential antiviral effect against alphaviruses [141]. Short interfering RNAs may
have antiviral effect against VEEV [188], and the rat zinc-finger antiviral protein
expression has been reported to inhibit SINV replication after virus penetration
and entry [21]. Ribavirin and human recombinant IFN-alpha have shown an anti-
CHIKV and anti-SFV effect in vitro [25].  Ribozymes  are  suggested  to  inhibit
alphavirus replication [219,262].
Avoiding mosquito bites is the cheapest, but often unreliable way to protect
oneself from alphavirus infection. Human vaccine prevention is currently
available for VEEV and EEEV. Against VEEV, an attenuated vaccine TC-83 and a
formalin-inactivated vaccine C-84 have been used [33,70]. Currently, a promising,
live-attenuated VEEV vaccine V3526 is being tested [202]. The current EEEV
vaccines are inactivated products [49] that have low immunogenicity, requiring
multiple inoculations and periodic boosters. No human WEEV vaccine is
available; however, adenovirus-vectored WEEV vaccine has shown promise in
mouse experiments [14]. A formaldehyde-inactivated RRV vaccine has been
preclinically promising [130]. Live CHIKV vaccine has undergone a phase II study
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in which it was proven reasonably safe and immunogenic [71]. There are no
clinically  used  or  pre-clinically  promising/safe  vaccines  for  the  other  human
pathogenic alphaviruses. Production of alphavirus infectious clones could be used
to create live attenuated vaccine candidates in the future [200].
6. OTHER ARTHRITOGENIC VIRUS INFECTIONS
In addition to alphaviruses, several other viruses are known or proposed to cause
joint manifestations. One of the major viral arthritides is human parvovirus B19
(genus Erythrovirus, family Parvoviridae) infection. B19 infection causes a variety of
clinical manifestations. In children, a peculiar erythema infectiosum is commonly
present  during  the  acute  phase,  but  arthropathy  is  rarely  seen  [186].  In  adults,
however, a symptomatic infection is characterized by polyarthritis that may
persist for months, and is more common in women than men [258].
Metacarpophalangeal joints, knees, and wrists are commonly affected [203].
Hematological or internal organ complications, or intrathecal infection may occur
[26].
Hepatitis  C virus  (genus Hepacivirus, family Flaviviridae) can often manifest with
extra-hepatic syndromes, including arthralgia (9% of the patients) or arthritis (4%)
[34]. Joint manifestations are sometimes seen in hepatitis B virus (genus
Orthohepadnavirus, family Hepadnaviridae) infection, as well, and its pathogenic role
in rheumatoid arthritis has been investigated [55].
Due  to  vaccine  coverage,  rubella  virus  (genus Rubivirus, family Togaviridae)
infection is rarely seen anymore in the western world. Arthritogenic
manifestations are typical of rubella infection, particularly in women. Arthritis has
been suggested as a complication of rubella vaccination [237]. Joint manifestations
are accompanied by rash and lymphadenopathy. Congenital rubella infection
leads to severe birth defects [13]. Mumps virus (genus Rubulavirus, family
Paramyxoviridae) is predominantly found in countries with poor vaccine coverage,
as well. Patients with mumps typically present with bilateral parotid swelling,
fever, and headache [104]. Arthropathy is more a complication than a typical
manifestation in mumps virus infection [101]. Other potential complications are
e.g. orchitis and meningitis [104].
– REVIEW OF THE LITERATURE –
SINDBIS VIRUS AND POGOSTA DISEASE IN FINLAND 35
Numerous clinical manifestations and associated infections are seen in patients
with human immunodeficiency virus (genus Lentivirus, family Retroviridae)
infection. Compared to general population, various rheumatic manifestations are
overrepresented in these patients [56]. Human T-lymphotropic virus type 1 (genus
Deltaretrovirus, family Retroviridae) infection can present with a chronic
arthropathy, which can be severe and destructive [185]. Joint symptoms are
sometimes seen in hantavirus infections, as well [138]. Certain herpesviruses have
been suggested as causative agents of joint manifestations, including Epstein-Barr
virus [53], cytomegalovirus [51], and varicella zoster virus [225].
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AIMS OF THE STUDY
Serological  evidence  for  the  association  of  SINV  and  clinical  syndrome
manifesting  with  rash-arthritis  was  first  noted  in  Northern  Europe,  in  the  early
1980s. Although SINV is prevalent in insects and vertebrates all around Eurasia,
Africa, and Australia, clinical disease in humans, known as Pogosta disease in
Finland, has almost exclusively been reported in Northern Europe. The molecular
biology of SINV is well known. In contrast, the clinical virology and epidemiology
are less investigated.
The specific aims of the study were to:
Develop and evaluate methods for the serodiagnostics of Pogosta disease
Establish the etiologic agent of Pogosta disease
Characterize the clinical picture of acute Pogosta disease
Study the long-term prognosis of Pogosta disease
Study the clinical virologic aspects involved in SINV infection
Characterize epidemiology of SINV infection in Finnish population
Search for factors contributing to the seven-year epidemiologic pattern of
Pogosta disease in Finland
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MATERIALS AND METHODS
PATIENTS AND MATERIALS
PATIENTS AND PATIENT SAMPLES (II, III, IV)
Original publications II, III, and IV describe  studies  on  a  cohort  of  patients
(Figure 5) recruited to the study in eleven health care centers in North Karelia and
in Kuopio University Hospital during a Pogosta disease outbreak in July-October
of 2002. Altogether 131 patients with clinically suspected acute Pogosta disease
participated in the study in eleven health stations in the province of North Karelia
and  in  Kuopio  University  Hospital,  Finland.  Of  these  patients,  86  had  an  acute,
serologically confirmed SINV infection. The acute-phase samples included serum
samples, whole blood samples in tubes containing ethylene diamine tetra-acetic
acid (EDTA) as anticoagulant, and skin lesion biopsies.
Case history reports on physician’s examination and basic blood parameters were
also available in most cases at the acute phase. New serum samples were collected
1-2 weeks and 5-6 months post infection from most patients. A questionnaire
study was carried out to collect descriptive information on the clinical picture of
Pogosta disease. The patients filled a questionnaire at the acute phase, and 5-6
months and 12-13 months post infection. The questionnaires focused on the
prevalence,  onset,  duration  and  anatomical  location  of  different  symptoms,  and
the patients’ subjective experience.
At three years post infection (median 39.3 months) in November-December 2005,
81  of  the  patients  could  be  re-invited  to  the  study  for  physical  examination  and
interview (IV). Serum samples were retrieved when possible. At this stage, 49/81
(60%)  of  the  patients  participated.  In  joint  examination  (performed  by  a  senior
rheumatologist), 72 joints were assessed for tenderness and 70 for swelling,
according to the EULAR handbook of clinical assessments [241]. Patients were also
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screened for spondyloarthropathy with the European spondyloarthropathy study
group criteria [69]. The general examination (performed by a general physician)
included cardiac and pulmonary auscultation, abdominal palpation, examination
of  skin  and  mouth,  and  palpation  of  lymph  node  areas.  Standardized  interview
was carried out by physicians. The interview dealt with the patient’s medical
history, current subjective joint symptoms (arthralgia or tenderness in joint
movement),  and  possible  temporal  association  of  current  symptoms  with  acute
SINV infection.
Figure 5.
Patients and material in original publications II, III, IV. The original cohort of 131 patients
was recruited during the 2002 Pogosta disease outbreak.
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SERUM SPECIMEN LIBRARY (I, V)
Specimen library consisting of serum samples sent to the Department of Virology
of the Helsinki University Central Hospital Laboratory during 1997-2003 for SINV
antibody  testing  was  used  for  the  development  and  evaluation  of  SINV  enzyme
immunoassays (EIA) (I), and for seroprevalence analysis (V).
For  the EIA development  (I), paired serum samples taken at approximately two-
week intervals from Finnish Pogosta disease suspected patients during 1997 1998
were selected. These included paired samples from 46 patients with acute SINV
infection confirmed with at least a four-fold rise in SINV HI antibody titers, and 40
first  samples  from individuals  in  whom the HI test  remained negative in  paired
samples. A third independent panel was randomly selected to determine
specificity of the assays, consisting of 42 first samples from patients in whom the
SINV HI test remained negative in two samples taken in 10 103 days interval.
All samples from 10/6/1999 to 5/8/2003 were included in the analysis of the
seroprevalence of SINV in Finnish population (V). If a patient had multiple
samples,  only the most  recent  sample was included in the study,  and those with
acute SINV infection (IgM-positive samples) were excluded.
DATABASE MATERIAL (V)
Since 1995, Finnish clinical microbiology laboratories have notified laboratory-
confirmed  diagnoses  of  SINV  infection  (by  antibody  detection)  to  the  National
Infectious Disease Registry maintained by the National Public Health Institute
(KTL). Each notification includes information on the date of specimen collection,
date of birth, sex and place of treatment. Using this information multiple
notifications for the same person which are received within a 12-month period are
combined as a single case. Data reported from January 1995 to December 2003
were included in the analysis of incidence of SINV in the Finnish population.
RESIDENT GROUSE BLOOD SAMPLES (V)
Blood samples from grouse were collected by hunters during hunting seasons
between 10 September and 31 October 2003, and 10 September and 31 October
2004.  Grouse  belong  to  the  order Galliformes, and family Tetraonidae; the species
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from which blood samples were collected were Capercaillie (Tetrao urogallus),
Black  Grouse  (Tetrao tetrix),  Hazel  Grouse  (Bonasa bonasia), and Willow Grouse
(Lagopus lagopus). The blood was absorbed into small filter paper slips, dried, and
stored individually in small plastic bags at -20 C. The hunters determined each
bird’s sex and whether it was a juvenile (born the same year) or an adult.
MIGRATORY BIRD BLOOD SAMPLES (V)
In 2004, blood samples were collected from migratory birds in two bird
observatories during their spring migration: in Jurmo Island (N 59°50’, E 21°36’;
EUREF-FIN) between 18 and 19 May and in Tauvo (N 64°49’, E 24°37’) between 24
and  27  May.  In  2005,  blood  samples  were  also  collected  in  two  different  bird
observatories during the spring migration: Lågskär Island (N 59°50’, E 19°55’)
between 22 and 25 May, and in Tauvo between 29 and 31 May. In addition,
migratory bird samples were collected in Kokkola archipelago (N 63°52’, E 23°04’)
on 30 July 2005.
Birds were captured with mist nets, and identified by bird ringers. Blood samples
were obtained by absorbing blood into filter paper slips from the veins of wings or
feet,  and  then  dried.  Native  blood  samples  were  also  harvested  into  small  glass
capillaries when possible.
CELL LINES (I, II, V)
The Vero and Vero E6 cell lines (both African green monkey kidney epithelial
cells) were originally obtained from the American Type Culture Collection, ATCC.
METHODS
VIRUS ISOLATION (II, V)
Virus isolation was attempted from human skin tissue and whole blood samples
(in  EDTA-tubes),  and  from  a  subset  of  the  bird  blood  samples.  The  frozen  skin
samples were cut into small pieces, then homogenized in a mortar, and suspended
in 100-150 l Dulbecco’s minimal essential medium (MEM) + 0.2% bovine serum
albumin (BSA). Confluent Vero cells in 25-cm2 cell culture flasks were inoculated
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with 50-100 l of this suspension diluted in 500 l of culture medium, containing
MEM and 2% fetal calf serum with a mixture of glutamine, ampicillin and
penicillin. Whole blood samples were diluted 1:10 in culture medium and
confluent Vero cell cultures were inoculated with the final volume of 500 l. The
cells were incubated for 1 h at 37 C, then 3-4 ml culture medium was added and
the cultures were kept at 37 C.
The toxicity of EDTA-anticoagulant on Vero cells could be avoided by completely
removing the blood dilution from cells after the 1-hour incubation, and also by
changing the culture medium the following day after the inoculation, and then
twice a week. All cell cultures were inspected daily. When CPE was apparent,
immunofluorescence assay (IFA) was performed and the cells were passaged.
RNA EXTRACTION (II, III, V)
Viral  RNA  was  extracted  from  virus  culture  supernatants  and  from  skin  tissue
samples by use of TriPure Isolation Reagent (Roche Molecular Biochemicals), and
from whole-blood samples by use of PAXgene Blood RNA Kit (PreAnalytiX). For
each experiment, negative (water) and positive (RNA from SINV supernatant,
always handled in a separate laboratory) controls were included.
NUCLEIC ACID DETECTION WITH RT-PCR (II, III, V)
Nested RT-PCR was developed for nucleic acid detection in the clinical samples
and bird blood samples. The sequences of primers (within the E2 region) designed
for the nested RT-PCR were as follows: 5’-ATACGAC(C/A)AAAGCGGAGCAG-3’
(outer forward [OF]), 5’AGTACGGGTCGTAACGGTTC-3’ (outer reverse [OR]), 5’-
GATACTTTCTCCTCGCGAAATG-3’ (inner forward [IF]), and 5’-
GTCTTGTAATCGCCGCACTTG-3’ (inner reverse [IR]).
For the RT reaction, RNA was incubated with 20 pmol of each outer primer, 40 U
of M-MuLV reverse transcriptase (MBI Fermentas), 5 pmol (0.22 mmol/L) of dNTP
mix (Finnzymes), and 80 U of ribonuclease inhibitor (MBI Fermentas) in RT buffer
(MBI Fermentas), in a total volume of 22.5 mL, for 90 min at 37°C.
For  the  outer  PCR,  10  mL  of  complementary  deoxyribonucleic  acid  (cDNA)  was
incubated at 95°C for 5 min, cooled immediately on ice, and mixed with 32 pmol
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of OF, 24 pmol of OR, 20 pmol (0.2 mmol/L) of dNTP mix (Finnzymes), and 2.5 U
of Taq DNA polymerase in PCR buffer with 200 mmol/L (NH4)2SO4 and  2.5
mmol/L MgCl2 (MBI Fermentas), in a total volume of 100 mL. The PCR conditions
were 39 cycles of 96°C for 45 s, 53°C for 45 s, and 72°C for 40 s; followed by a final
extension for 10 min at 72°C.
For the inner PCR, 5 mL of the outer PCR product was mixed with 28 pmol of each
inner primer, 25 pmol (0.25 mmol/L) of dNTP mix (Finnzymes), and 2 U of Taq
DNA polymerase (MBI Fermentas), as described above. The PCR conditions were
39 cycles of 95°C for 60 s, 56°C for 45 s, and 72°C for 30 s; followed by a final
extension for 10 min at 72°C.
The products were stained with ethidium bromide and run in SeaKem LE agarose
(BioWhittaker Molecular Applications). The sensitivity of the PCR assay was
determined to be ~0.1 infectious virions, by use of SINV supernatant (titrated with
plaque titration) as a control.
CLONING, SEQUENCE ANALYSIS AND PHYLOGENY (II)
Phylogenetic analysis was performed within the nucleotide sequences of 1,178–
1,281 bp from nsP3 and nsP4 region (nucleotides 5,258-6,510; the genome position
is given according to the published sequence of the strain AR339 (HRsp variant)
[227]).  The  PCR  amplicons  were  purified  with  QIAquick  gel  extraction  kit
(Qiagen). The amplicons were cloned with TOPO TA Cloning Kit for Sequencing
(Invitrogen), following the manufacturer’s instructions, and transformed into
TOP10 chemically competent E. coli cells on bacterial plates containing x-gal (5-
bromo-4-chloro-3-indolyl-ß-D-galactoside) and IPTG (isopropylthio-ß-D-
galactoside) for blue-white screening. The plasmid DNA was isolated with
QIAprep miniprep kit (Qiagen) and restriction analysis was performed. Vector-
based primers M13 Reverse and T7 were used for automatic sequencing with ABI
PRISM.
Sequences were aligned with Clustal W 1.75 program [235] into MSF-format and
edited with GeneDoc multiple sequence alignment editor program. Sequence was
confirmed from at least three different clones. PHYLIP program package
(Felsenstein, 1993) was used to create 5000 bootstrap replicates on the sequence
data (SEQBOOT). Distance matrices were calculated with DNADIST program
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with Kimura’s two-parameter model of substitutions and analyzed by Neighbor-
joining tree-fitting algorithm with NEIGHBOR program. The bootstrap support
values were calculated with CONSENSE program.
SINV IGM AND IGG EIAS (I, II, III, IV, V)
SINV IgM and IgG EIA methods were developed and evaluated as a part of this
study (I).
Virus production for the EIAs
SINV (Edsbyn 82/5 [181]) was propagated in Vero cells in MEM, 0.2% BSA,
glutamine-penicillin-streptomycin. Cell culture supernatants were collected at
50% cytopathic effect, and centrifuged in Sorvall GSA rotor for 15 min at 1000 x g
at +4°C. The resulting supernatant was filtrated (0.22 µm) and ultracentrifuged in
Beckman  SW  28  rotor  for  3.5  h  at  122,000  x  g  at  +4°C.  The  pellet  was  eluted
overnight  in  300  µl  of  50  mM  Tris-HCl  and  1  mM  EDTA  pH  7.5  at  +4°C,  water-
sonicated for 5 min on ice, and used as EIA antigen. To confirm quality, the virus
was examined with electron microscopy.
Coating of the EIA plates
The antigen was inactivated with 10% N-octyl- -D-glucopyranoside (20:1) for 15
min on ice, and water-sonicated for 8 min on ice. Box titration was performed to
find out the optimal antigen dilution, which was 1:2500 in phosphate-buffered
saline (PBS). After coating with 100 µl of antigen dilution at room temperature
overnight, 96-well-plates were washed five times with PBS + 0.05% Tween 20, and
blocked  with  100  µl  of  3%  BSA  in  PBS  for  1  h  at  room  temperature.  The  plates
were once washed, and stored at -70°C.
IgM and IgG EIAs
Diluted sera (1:200 in PBS + 0.05% Tween 20 + 0.5% BSA) were incubated for 60
min at +37°C on antigen-coated wells, washed 5 times with PBS + 0.05% Tween 20,
again incubated for 60 min at +37°C with 100 µl of horseradish peroxidase labeled
rabbit-anti-human IgM (1:1600) or IgG (1:4000) (DakoCytomation), and washed.
The substrate reaction with 100 µl of 3,3',5,5'-tetramethyl benzidine (Sigma-
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Aldrich) was stopped with 100 µl of 0.2M H2SO4 after 10 min, and the optical
density (OD) values were read within 30 min by a spectrophotometer at 450 nm.
ELECTRON MICROSCOPY (I)
Propagated and purified virus was applied on carbon-coated grids and negatively
stained with potassium phosphotungstate (2%, pH 7.2). The grids were examined
with Jeol JEM-100 CXII electron microscope.
HI TEST (I, II, III, IV, V)
HI  test  was  used  as  the  primary  screening  method  for  bird  blood  filter  paper
solutions, and as a specificity control and for evaluation of the EIAs. The method
was modified from Clarke and Casals (1958) [46]. Sera diluted 1:5 in borate pH 9.0
+ 0.6% BSA were adsorbed with an equal volume of 25% kaolin (in borate pH 9.0),
shaken for 20 min at room temperature, and centrifuged for 20 min at 700xg at
+4°C.  Erythrocytes  were  separated  from  male  goose  blood,  and  washed  with
dextrose-gelatin-veronal buffer and penicillin-streptomycin. The samples (500 µl)
were adsorbed with 50 µl of 50% erythrocytes (in dextrose-gelatin-veronal buffer
and penicillin-streptomycin) at +4°C for 20 min, while lightly shaken every 5 min.
After centrifugation for 10 15 min at 400 x g at +4°C, the resulting supernatant was
separated.
Pre-treated samples underwent two-fold microtitration on 96-well-plates (25 µl
per  well;  diluted  in  borate  pH  9.0  +  0.6%  BSA),  and  were  incubated  with  3
hemagglutinating units (25 µl) of Tween-ether-treated SINV supernatant (strain
AR339 [232], grown in Vero cells) overnight at +4°C. Tween-ether-treatment was
done under a hood on ice and inactivation of the antigen was confirmed on Vero
cell cultures. Separate microtitration confirmed correct antigen concentration.
Goose erythrocytes (1:10 in dextrose-gelatin-veronal buffer + penicillin-
streptomycin) were further diluted with 0.20 M NaH2PO4 and  0.20  M  Na2HPO4
(both in 0.15 M NaCl) to a final 0.2% suspension (pH 6.0), of which 50 µl was
added  on  each  well,  and  kept  at  room  temperature.  The  HI  result  was  read  1  h
later.
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NT (I, V)
NT was used as a confirmatory method for EIA and/or HI with human sera or bird
blood filter paper slip solutions. Endpoint titers of neutralizing antibodies against
SINV-prototype strain AR339 were determined by detecting inhibition of CPE on
confluent monolayers of Vero E6 cells. The sera or bird blood filter paper slip
solutions were diluted in culture medium containing MEM and 2% fetal calf
serum with a mixture of glutamine, ampicillin and penicillin. 300 µl (containing
approximately 50 plaque forming units) of virus dilution was mixed with an equal
volume of serial fourfold serum dilutions, followed by incubation for 1 h at +37°C.
Vero  E6  cells  were  subsequently  inoculated  with  200  µl  of  this  mixture,  and
incubated for  1  h  at  +37°C.  1.5  ml  culture  medium was added on each well.  The
endpoint titers in which CPE was inhibited were determined approximately 65 h
post infection.
IFA (I, II)
An  IFA  was  developed  to  confirm  SINV  infection  of  the  cells  in  virus  isolation
experiments (II),  or  conversely,  to  detect  SINV  antibodies  in  serum  samples  (I).
Vero  cells  (from  virus  isolation  experiments  or  inoculated  with  SINV)  were
harvested (in 600 l PBS in virus isolation experiments), washed and centrifuged
at 1800 rpm for 3 min x 5 and dried on a slide. For immunofluorescence staining
the slides were fixed for 7 min in ice-cold acetone. A pool of 10 SINV IgG-positive
sera or the test serum was diluted 1:20 in PBS, added to slides and incubated in a
moist chamber at 37 C for 30 min. The slides were washed three times in PBS and
once in  aqua,  then incubated at  37 C for 30 min with fluorescein isothiocyanate-
conjugated F(ab')2 goat anti-human IgG diluted 1:100 in PBS. After another wash,
the slides were dried, mounted and screened with a fluorescence microscope.
IMMUNOBLOTTING (I)
Immunoblotting was used to characterize the antigenic proteins of the SINV EIA
antigen. Non-reduced (dissolved in Laemmli sample buffer) and reduced
(dissolved in Laemmli sample buffer with 2-mercaptoethanol (10 w/v %)) SINV
preparates  were  separated  by  10%  and  8-16%  non-reducing  sodium  dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Coomassie staining was
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performed to reveal protein bands. The SDS-PAGEs were transferred into
nitrocellulose filters and immunoblotted with sera (diluted 1:50) according to
standard  protocols,  using  polyclonal  rabbit  anti-human  IgM  or  IgG
(DakoCytomation). The reaction was detected by enhanced chemiluminescence
[194].
IMMUNOHISTOCHEMICAL ANALYSIS (III)
Immunohistochemical analysis was used for skin tissue samples. The skin biopsy
specimens were fixed in 10% formalin and embedded in paraffin blocks. The
immunohistochemistry  assay  was  performed  on  two  thin  sections  cut  from  each
block and mounted on Super Frost (+) slides (Menzel-Gläser). Ventana Discovery
(Ventana Medical Systems) was used for DAB (3,3’ diaminobenzidine) staining.
The tissue sections were deparaffinized, and incubated for 20 min with a mixture
of  three  different  sera  of  mice  infected  with  SINV  (two  with  the  strain  Ockelbo
Edsbyn 82/5 and one with Ockelbo 520; kindly provided by Sirkka Vene, Swedish
Institute  for  Infectious  Diseases  Control)  in  1:1500  dilution.  The  samples  were
counterstained with hematoxylin and evaluated with light microscopy. A skin
biopsy specimen from a serologically confirmed SINV–negative patient was used
as  a  negative  control  sample.  A  positive  control  sample  was  created  from  SINV-
infected Vero cells (dispersed in 4% agarose) that were formalin-fixed and
paraffin-embedded.
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RESULTS AND DISCUSSION
The  results  of  this  study,  based  on  the  original  contributions  (I-V) and
unpublished data, are summarized below. The study describes serodiagnostic
methods for human SINV infection, the etiologic agent of Pogosta disease, clinical
and laboratory manifestations of the disease, and epidemiology of SINV infection
in Finland.
1. SERODIAGNOSIS OF SINV INFECTION (I)
The EIA methods described below were used for the serodiagnostics of the
patients throughout the study.
EIA FOR THE SERODIAGNOSTICS OF SINV INFECTION
During the Pogosta disease epidemics in Finland, thousands of serum samples are
sent to the laboratory within a few months time for SINV antibody testing. Due to
requirements on time- and cost-effectiveness, the previously published methods
[40,242] were not compatible for our diagnostic purposes. Therefore, we set up
IgM and IgG EIAs based on highly purified SINV, and evaluated the methods by
comparison to HI, IFA, and NT.
Assay cut-offs were determined with 40 confirmed negative samples (Figure 6).
The EIAs were evaluated with paired serum samples from 46 patients (I:  Fig.  1),
who all  showed neutralizing antibodies  in  either  sample,  and at  least  a  four-fold
rise in HI titers between the samples (I:  Table  1).  The  sum  of  IgM  and  IgG  OD
values compared to HI titers correlated significantly, Pearson’s r = 0.406,
significance level (one-tailed) = 0.001 (only HI-positive samples included, N=62) (I:
Fig. 2).
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The sensitivity of the IgG EIA was 100% (46/46 positive), and IgM EIA 97.8%
(45/46 positive; the negative sample was, however, taken 26 days after onset of
symptoms), as determined with the second samples from the positive panel. All
the  second  samples  were  positive  (titer  20)  also  in  the  IgG  IFA  analysis.  The
specificity of the IgG EIA was 97.6% (1/42 false grey zone) and IgM EIA 95.2%
(2/42 false-positive), determined with an independent negative panel.
The EIAs developed where shown to meet the desired requirements: the antigen
production  is  fairly  simple,  but  at  the  same  time,  the  methods  are  adequately
sensitive, and specific, especially when HI and EIA are performed in parallel.
However, in the future, development of EIAs based on e.g. µ-capture format could
further improve the reliability of the serodiagnosis of SINV infection.
Figure 6.
40 serum samples from patients negative for SINV HI antibodies were twice analysed with
SINV IgM and IgG EIA.  Each  dot  represents  the  mean value  of  two analyses,  subtracted
with  the  mean  value  of  eight  blank  wells.  Assay  cut-off  was  determined  by  calculating
mean plus 3 SD. Grey zone determined for the assay is shown in grey. 1/40 samples gave a
borderline result (arrow), while all others remained negative A. IgM EIA, B. IgG EIA. OD,
optical density.
A
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B
ANTIGENIC PROPERTIES OF THE PURIFIED SINV USED AS EIA ANTIGEN
The described EIAs are based on highly purified SINV grown in Vero cell cultures.
To characterize the antigenic proteins of the EIAs, the antigens were separated
with  SDS-PAGE  (I:  Fig.  3)  and  immunoblotted  (I:  Fig.  4).  Convalescent  serum
samples of patients with SINV infection had strong reactivity against both E1 and
E2 in IgM and IgG immunoblots. Also in one of the first samples (46I), IgM reacted
with E2, and faintly with E1. A strong IgM response was seen against C protein in
sample 46II; however, C protein showed background signal in immunoblot in all
samples, including the negative sera. Thus, both E1 and E2 appear to contribute to
the antigenicity in the IgM and IgG EIAs described. The antigenic role of C protein
in early infection remained unclear. According to literature, SINV E1 is responsible
for hemagglutinating activity of the virus, whereas neutralizing activity is targeted
against E2 [208]. It is evident that the majority of the neutralizing activity is due to
IgM  response  in  the  early  samples,  whereas  in  the  late  samples  the  activity  is
largely due to IgG, which could explain the lack of differences in NT titers in some
individuals in our study.
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DIAGNOSTIC CRITERIA
The risk for false-positive diagnosis of acute disease using the IgM EIA described
is less than 4.8%, because of further verification of the specificity of the reaction by
HI and the following diagnostic criteria for acute SINV infection: (1) in addition to
a positive IgM result, a 4-fold increase in HI (or IgG) titer between paired sera or
(2) a positive IgM result and a negative/borderline IgG result (which excludes old
immunity)  and  specific  reaction  in  HI  (titer  >10).  A  positive  IgG  and  HI  result
confirm previous immunity.
IgM antibodies to alphaviruses are complex-specific [37]. The EIAs described here
could be cross-reactive with other alphaviruses. This is not a considerable problem
in Northern Europe, since besides SINV, no other alphaviruses are known to
circulate in the region. However, travelers’ imported infections, e.g. CHIKV, are an
exception.
2. ETIOLOGY OF POGOSTA DISEASE (II)
Prior  to  the  present  study,  SINV  had  been  isolated  from  a  human  sample  twice:
from the vesicle fluid of skin lesions taken from a 45-year-old woman with acute
rash-arthritis in South Africa in 1963 (Girdwood strain) [164], and from the serum
sample of a febrile patient in China in 1992 (YN87448 strain) [263]. Although it has
been  generally  accepted  that  SINV  or  a  virus  closely  related  to  SINV  is  the
causative agent of the rash-arthritis syndrome, Pogosta disease, in Finland, the
association was thus far only based on serological evidence [28,31].
We confirmed the etiology of Pogosta disease by isolating SINV from five acutely
ill patients with serologically confirmed SINV infection (II: Fig. 1, Table). The
isolates  were  confirmed  positive  with  IFA,  nested  RT-PCR,  and  subsequent
sequence  analysis.  Of  the  isolates  four  were  recovered  from  a  skin  tissue  biopsy
specimen, and one from a whole blood sample. These strains, representing the
first  SINV  isolates  from  Finland,  confirmed  that  SINV  is  the  etiological  agent  of
Pogosta disease, and are the first human SINV isolates from Europe.
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3. CLINICAL PICTURE OF ACUTE POGOSTA DISEASE (III)
Two previous studies have outlined the most typical symptoms of acute Pogosta
[239] and Ockelbo [76] disease as arthritis, rash, and fever. To further characterize
the clinical picture of the acute infection, we studied 86 patients with serologically
verified  acute  SINV  infection  in  North  Karelia  during  the  2002  Pogosta  disease
outbreak. See Figure 5 for the material available for this study.
The clinical picture (III:  Table  2)  of  the  acute  SINV  infection  consisted  of  joint
symptoms, itching rash (III: Fig. 1), fatigue, mild fever, headache and muscle pain,
usually beginning within the first two days of illness (III: Table 2). Ankle, finger,
wrist and knee joints were most commonly affected (III: Fig. 2), and usually three
or more joints were ill, manifesting with tenderness in movement and ache, but
commonly also with edema (III: Table 3). Typically the joint symptoms occurred in
a fluctuating manner, but not changing the anatomical location. There was no
considerable difference in symptoms according to the time of the day (III: Table 3).
The rash was usually located in trunk and thighs (III: Fig. 2).
In  one of  the patients  from whom the clinical  timeline was well  documented the
incubation period was probably 8-9 days (III: Fig. 3). However, further evidence is
required to establish the incubation period for SINV infection. For comparison, in
RRV infection, the incubation period is 7-9 days [89]. Most patients considered the
subjective handicap and need for daily adjustments in their everyday lives during
the symptomatic phase of the infection mild or moderate, but more than one third
graded the subjective handicap considerable or major (III: Table 4).
Clinical hematological and infection laboratory parameters were analyzed at the
acute phase. All parameters studied were within normal range in almost all cases
(Table 2).  In  addition  to  the  86  patients  with  verified  SINV  infection,  28
seronegative and 6 old-immunity patients were initially recruited to the study. In
comparing  the  patients  with  and  without  acute  infection,  it  became  evident  that
arthritis and rash were only somewhat less frequent in the latter. Thus, diagnosis
of acute SINV infection should always be verified serologically; clinical diagnosis
alone is not reliable.
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Table 2.
Clinical hematological findings from patients who had acute SINV infection. Patients under
the age of 17 have been excluded from this table due to different normal range values.  F,
female;  M,  male;  WBC,  white  blood  cell  count;  RBC,  red  blood  cell  count;  MCV,  mean
corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular
hemoglobin concentration; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
4. PROGNOSIS OF POGOSTA DISEASE (III, IV)
PERSISTENCE OF JOINT MANIFESTATIONS
Several reports have suggested that joint symptoms in arthritogenic alphavirus
infections can persist for months or even years, but most of these studies have
been carried out with self-administered interviews without examining the patients
[17,50,178,180,182,218,242]. In a single previous clinical study on SINV infection
performed by Laine et al. with 26 patients 2.5 years after serologically confirmed
SINV infection, prolonged joint manifestations were present in 42% of the patients
[133].
To  further  shed  light  into  the  possible  prolonged  manifestations  of  Pogosta
disease, we followed our patients, recruited to the study during the 2002 outbreak,
first by means of self-administered questionnaires at 5-6 months and 12-13 months












WBC, E9/L 5.7 5.3 1.9-10.7 43 3.6-10.1
RBC, E12/L 4.4/5.0 4.5/5.1 3.4-5.2/4.2-5.4 32/8 4.0-5.3 / 4.5-6.1
Hemoglobin, g/L 133/155 133/155 105-149/128-170 34/9 125-160 / 135-180
Hematocrit, % 39/44 39/46 33-44/37-47 33/9 37-47 / 40-54
MCV, fL 88 89 72-104 42 80-96
MCH, pg/cell 30 31 24-37 42 27-32
MCHC, g/L 344 343 320-366 40 320-360
Platelet count, E9/L 228 218 144-373 41 150-400
Lymphocyte % 33.1 32.2 15.2-53.2 30 20-45
Neutrophil % 56.5 60.0 35.5-79.0 27 40-75
CRP, mg/L - - <5-20 15 <10
ESR, mm/h 12/3 14/3 2-22/3-3 10/1 1-10 / 1-8
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In the 12-13-month follow-up questionnaire study (III), 50% of the patients
reported that joint symptoms were still present at 12 months post infection (III:
Table 3). The duration of joint symptoms was significantly dependent on age: the
average age for those with symptoms for more than a year was 46 years, whereas
it was 35 for those with full recovery (Student t-test, p = 0.014). Although females
manifested with prolonged symptoms more often than men, the difference was
not significant (Chi-Square test, p = 0.0729).
The proportion of patients reporting prolonged joint manifestations was
surprisingly high. However, the methodology used (self-administered
questionnaires) is susceptible to errors of recall or other mistakes, bringing on
limitations in the interpretation of the results. Therefore, another, more reliable
approach was undertaken: we physically examined the same patients three years
after the infection to reveal objective joint manifestations that could be linked with
SINV  infection  (IV).  The  rheumatologic  assessment  was  performed  by  a  senior
rheumatologist, and the general examination by a general physician. In all, 49
patients could be recruited at this stage (60% of the 81 that could be invited) (IV:
Table 1).
The joint examination revealed several findings according to which the patients
were categorized into groups A-D (IV: Table 2). Arthritis, which was determined
as swelling and tenderness in the joint in the physician’s examination, was
diagnosed in 2/49 (4.1%) of the patients (Group A). Tenderness in palpation or in
joint  movement  was  found  in  14.3%  of  the  patients  in  the  rheumatologic
examination (Group B), whereas additional 10.2% of the patients complained of
arthralgia at the interview (Group C); thus a total of 24.5% of the patients had such
joint  symptoms  that  could  be  linked  with  the  SINV  infection  three  years  earlier
(IV:  Table 3). Patients in Group D (75.5%) had no clearly defined joint symptoms
that could be associated with SINV infection.
The prevalence of persistent joint pain caused by SINV infection shown in this
study is in agreement with previous studies. However, our results suggest that
persistent arthritis, requiring both swelling and tenderness in examination, is not a
typical manifestation, and should be distinguished from mere pain.
It can be estimated that solely in the province of North Karelia, which is a highly
endemic  area,  and  where  this  study  was  carried  out,  several  hundred  patients
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manifest  with  chronic  arthritis,  and  a  few  thousand  people  from  arthralgia  as
sequelae of SINV infection. Consequences and clinical significance of Pogosta
disease could be considerable, and it is important to consider prolonged
symptoms of SINV infection as a possible cause of persistent and undefined joint
symptoms in areas with high seroprevalence.
The persistent disease mostly affected small and peripheral joints. The number of
(subjectively) affected joints of the patients in the groups A-C increased in 4/12,
remained the same in 2/12, and decreased in 6/12 of the patients as compared to
the acute phase; 69% of the affected joints were ill also during the acute phase.
Frequency  of  persistent  joint  symptoms  could  not  be  associated  with  gender  or
age. None of the patients in groups A-C fulfilled the criteria of
spondyloarthropathy.
One of the patients had been diagnosed with Sjögren’s syndrome and one with
polymyalgia rheumatica during the three-year follow-up. Whether SINV infection
can initiate autoimmune diseases remains a subject for further investigation. There
was no significant difference in the history of other musculoskeletal diseases
between patients in group A-C and group D.
Our study arrangement differed from the clinical study performed by Laine et al.
at the end of 1990s [133]. The patients in that study were examined by a general
physician, and those patients having joint symptoms were examined by a
rheumatologist.  In  the  present  study  all  patients  were  examined  by  a
rheumatologist. In our study, general examination was performed on each patient
by  a  general  physician,  and  we  had  records  of  each  patient’s  acute  phase
(questionnaire forms fulfilled during the acute phase), thus our study was
prospective. This allowed us to compare the number of joints affected at the acute
phase and three years  post  infection.  We were also able  to  compare whether  the
same joints were affected at these two stages. We classified our patients according
to the severity of their symptoms. We took into account whether the findings were
subjective or objective, as well as the temporal association of the symptoms to the
infection three years earlier, and report the exact joints that were affected (number
of patients, number of joints, anatomic location), not available in previous studies.
Studies reporting persistent joint manifestations after an alphavirus infection are
summarized in Table 3. Our results are in agreement with the previous reports on
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SINV,  as  well  as  on  RRV.  Comparison  to  CHIKV,  BFV,  MAYV,  and  ONNV  is
difficult, as only few studies have been performed, and only with small number of
patients. Conclusion from our studies and those by Laine et al. [133] is that Pogosta
disease causes persistent joint manifestations, sometimes even chronic arthritis,
but  our  data  indicate  that  persistent  arthritis  continuing  for  years  is  not  a  very
typical manifestation.
Table 3.







% of patients with
residual joint
manifestations Study setting Additional information Reference
SINV 86 3-4 years 24* questionnaire andtelephone interview





Niklasson et al  1988
SINV 16 2.5 years 31 telephone interview Vene et al  1994
SINV 60 > 1 month 55 self-administeredquestionnaire
Turunen et al  1998
SINV 26 2.5 years 42 clinical examination 8% had arthritis Laine et al 2000
SINV 1 > 4 years clinical examination the patients hadosteoarthritis Luukkainen
et al 2002
SINV 64 > 12 months 50 self-administeredquestionnaire
III
SINV 49 3 years 25 clinical examination 4% had arthritis IV
RRV 255 24-42 months 57 self-administeredquestionnaire
Condon and Rouse
1995
RRV 436 13 months 12 self-administeredquestionnaire 3% reported swollen joints
Selden and Cameron
1996
RRV 47 2.3-6.5 months 68 standard questionnaire Harley et al  2002
CHIKV 28 20 months 18 clinical examination Fourie and Morrison1979
CHIKV 20 4-16 months 60-70 clinical examination Kennedy et al  1980
CHIKV 1 clinical examination destructive arthropathy for15 years
Brighton and Simson
1984




Beard et al  1997
BFV ? ?
~10% have joint
tenderness at 6 months
post infestion, unpublished
data reported in this review
Flexman et al  1998
MAYV 2 subjective report a few months of joint painafter infection
Tesh et al  1999
MAYV 1 clinical examination recurrent arthralgias Taylor et al  2005
ONNV ? ? "protracted" disease "insome patients" Shore 1961
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PROGNOSIS OF EXTRA-ARTICULAR MANIFESTATIONS
According to the questionnaire study carried out with the Pogosta disease
patients, defervescence typically occurred within a few days, but rash and fatigue
often lasted for more than 5 days (III: Table 2). At three years after infection, the
patients (n=49) were physically examined by a physician to reveal any extra-
articular manifestations. The examination included cardiac and pulmonary
auscultation, abdominal palpation, examination of skin and mouth, and palpation
of  lymph  node  areas.  None  of  the  patients  had  such  extra-articular  findings  at
three years post infection that could be linked with SINV infection (IV), consistent
with previous reports.
5. ANTIBODY RESPONSE AND PRESENCE OF VIRUS IN TISSUES
DURING HUMAN SINV INFECTION (II, III, IV)
ANTIBODY KINETICS (III, IV)
To facilitate the interpretation of SINV serodiagnostics, we aimed to characterize
the antibody kinetics in SINV infection. Serial serum samples of 50 patients taken
during 0-6 months post infection were analyzed for the presence of IgM and IgG
antibodies (III: Fig. 4a-f). IgM antibodies became detectable within the first 8 days
of illness, and 36% of the patients had IgM antibodies detectable 5-6 months post
infection  (two  of  them  were  positive  in  rheumatoid  factor  testing).  In  the  first
serum samples, 48% of the 86 patients had a positive IgM result, and 16% of the
patients had a borderline result. IgG antibodies became detectable within the first
11 days of illness. To conclude, a negative result in SINV antibody testing during
the first week of illness does not rule out Pogosta disease, and a paired sample is
required.
A serum sample was retrieved from 44 patients at three years post infection (IV).
SINV  IgM  antibodies  were  detectable  (after  removal  of  IgG  antibodies)  in  3/44
(6.8%) of  the samples,  and a  borderline IgM result  was detected in  an additional
3/44 (6.8%) of the samples. Persisting IgM antibodies complicates the distinction
between acute infection and previous immunity; the problem could be solved by
developing an appropriate IgG-avidity test in the future.
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Both patients with arthritis had IgM antibodies detectable in their serum samples
at  three  years  post  infection  (IV: Table 3). Although IgM antibodies have
previously  been  shown  to  persist  even  for  several  years  post  infection,  no
correlation between persisting IgM and prolonged joint symptoms has been stated
[182]. Due to limited number of samples, we could not show statistical significance
either. Persisting IgM antibodies could suggest that viral replication takes place
somewhere in the body, possibly in synovia, periarticular tissues, muscle cells, or
elsewhere.
DETECTION OF SINV IN BLOOD AND SKIN (II, III)
Previously,  SINV  RNA  has  been  detected  by  PCR  in  skin  lesions  of  Swedish
Ockelbo disease patients [118]. We collected both skin lesion biopsy specimens
and whole blood samples from acutely ill patients with serologically verified SINV
infection.  Virus  isolation  was  successful  from  4/23  skin  lesion  samples  and  from
1/73  whole  blood  samples  (II).  SINV RNA could be detected by RT-PCR in 4/23
skin  lesions,  and  in  5/73  whole  blood  samples  (III).  Altogether,  SINV  could  be
isolated or detected by RT-PCR (or both) from 8/86 patients (Table 4). These
samples were taken during the first 2-9 days of illness (data available from 6/8
cases). No SINV antigen was detected in the 21/23 of the skin biopsies analyzed by
immunohistochemistry. Two of the skin lesion specimens were negative with RT-
PCR, although virus isolation was successful. This could be due to a varying viral
load in different sections of the skin, possibly related to the amount of blood in the
skin tissue.
The cell type in which SINV replicates in skin tissue is not known. Histopathologic
examination of skin lesions of Pogosta disease patients has previously revealed a
pronounced lymphohistiocytic inflammatory infiltrate and lymphoblast-like cells
[11]. Since the virus is present in the skin during acute infection before the onset of
antibody response (II: Table), the cutaneous manifestations in Pogosta disease may
be due to a direct viral effect – or the pathogenesis could involve a more complex
immunologic reaction.
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Table 4.
Serological findings and detection of SINV from skin lesion biopsy specimens and whole
blood samples taken from acute patients who had acute SINV infection. The 8 patients from
whom  SINV  RNA  could  be  detected  or  virus  isolation  was  successful  (or  both)  are
presented separately (P1-P8).  See III: Fig. 3 for the clinical timeline of the patient 5 (P5) and
III: Fig. 1 for the photograph of the rash of patient 7 (P7). N/A, sample not available. *IgM
status not known at the time of sampling the skin lesion, since serum sample was taken 9
days before that.
6. EPIDEMIOLOGY OF SINV IN FINLAND (II, V)
MOLECULAR EPIDEMIOLOGY OF SINV STRAINS FROM FINLAND (II)
The five new SINV strains that we isolated from acutely ill  patients in Finland in
2002 were further characterized by phylogenetic analysis of the nucleotide
sequences of 1,178–1,281 bp from nsP3 and nsP4 region, nucleotides 5,258-6,510;
the  genome  position  is  given  according  to  the  published  sequence  of  the  strain
AR339 (HRsp variant) [227]. The phylogenetic tree was constructed by using
neighbor-joining tree-fitting algorithms. The strains were given the following
accession numbers: Ilomantsi-2002A (AY532322), Ilomantsi-2002B (AY532326),
Ilomantsi-2002C (AY532324), Kiihtelysvaara-2002 (AY532325), and Johannes-2002
(AY532323). In addition, we sequenced from this region the LEIV-9298-strain
(AY532321) [159], isolated from Aedes mosquitoes in 1983 in central Russian
Karelia, approximately 200 km north of Ilomantsi, Finland.
The following sequences available in GenBank were included in the comparison:
AR339  (HRsp  variant),  Girdwood  S.A.,  MRE16,  Ockelbo  (Edsbyn  82),  S.A.AR86,
SW6562, YN87448, and XJ-160 (II: Fig. 1). Sequence comparisons (Table 5) and
phylogenetic analysis (II:  Fig.  2)  showed  that  Finnish  SINV  strains  are  closely
All Individual patients
N % P1 P2 P3 P4 P5 P6 P7 P8
Negative 31/86 36 x x x x* x
Borderline 14/86 16 x x x
SINV IgM status
in first serum
sample Positive 41/86 48
SINV RNA detectable in blood 5/73 7 + + + - + - - +
Virus isolation from blood 1/73 1.4 - - + - - - - -
SINV RNA detectable in skin 4/23 4 + - N/A - + + + -
Virus isolation from skin 4/23 17 + + N/A + + - - -
Immunohistochemistry on skin 0/21 0 - - N/A - - - - -
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related  to  each  other  and  to  the  Swedish  and  Russian  strains,  isolated  from
mosquitoes two decades earlier; these strains seem to share a common ancestor.
The percentage difference of these strains was 0.1% to 1.4% on nucleotides, and
0% to 2.1% on amino acids.  The Russian Karelian LEIV-9298 and Johannes differ
by one nucleotide, and their amino acid sequences are identical in the analyzed
region.
This analysis could indicate that Northern European SINV strains are maintained
locally in disease-endemic regions. However, South African SINV strains do not
differ  substantially  from  Swedish  strains  [166]  or  from  the  Finnish  strains  in  the
present study. The question remains whether the yet unknown resident reservoir
species are able to sustain SINV cycle in Northern Europe endemically or whether
it  is  crucial  that  the  virus  is  repeatedly  introduced  there  from  the  southern
hemisphere. Migratory birds would be plausible viral carriers from faraway
distances, such as Africa.
INVOLVEMENT OF BIRDS IN THE EPIDEMIOLOGY OF SINV (V)
The phylogenetic studies on the novel Finnish SINV strains (II) and the data
reported by Norder et al.  [187]  inspired us  to  look for  factors  contributing to  the
peculiar  epidemiologic  pattern  of  human  SINV  outbreaks  every  seven  years  in
Finland. The observation that in the 1970s and the 1980s, the human outbreaks and
crashes of the grouse population seemed to coincide (Figure 7), and the detection
of SINV antibodies in Finnish [31] and Swedish [154] birds in the late 1980s,
focused our interest on resident grouse.
Since  the  phylogenetic  analyses  also  supported  the  hypothesis  that  SINV  is
redistributed in a longitudinal, not latitudinal, direction, studying migratory birds
became of particular interest, as well. Indications of periodic redistribution of
SINV  strains  over  long  distances  and  within  a  short  time  have  previously  been
demonstrated in Australia [213], a finding consistent with the involvement of
migratory birds. Furthermore, studies on antigenic relatedness of alphaviruses
have  also  suggested  that  progenitor  alphaviruses  are  spread  over  long  distances
by birds [39].
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Table 5.
Nucleotide and amino acid differences of the analyzed SINV strains. Percentage differences
of the strains on nucleotides (above the diagonal) and amino acids (below the diagonal).
Figure 7.
Annual late summer density estimates of grouse in the North Karelia game management
district, based on route censuses in 1967-1988 and the wildlife triangle scheme in 1989-2006
(methods: Lindén and Rajala 1981 [145], Lindén et al. 1996 [144]; source: Finnish Game and
Fisheries Research Institute). The vertical lines show the Pogosta disease outbreaks in



















































































































Ilomantsi-2002A 0.6 0.6 0.3 0.4 0.5 1.4 8.3 5.2 7.4 5.0 26.5 35.8 33.3
Ilomantsi-2002B 0.5 0.3 0.2 0.2 0.2 1.2 8.0 5.0 7.2 4.8 26.4 35.6 33.4
Ilomantsi-2002C 0.7 0.7 0.2 0.2 0.3 1.1 8.0 5.0 7.0 4.8 26.4 35.6 33.3
Kiihtelysvaara-2002 0.2 0.5 0.7 0.1 0.2 1.1 8.0 4.9 7.1 4.7 26.3 35.6 33.3
Johannes-2002 0.2 0.2 0.5 0.2 0.1 1.0 7.9 4.8 7.0 4.7 26.3 35.6 33.3
LEIV-9298 0.2 0.2 0.5 0.2 0 1.1 8.0 4.9 7.1 4.7 26.5 35.6 33.4
Ockelbo (Edsbyn 82) 2.1 1.4 1.4 1.4 1.2 1.2 7.8 5.7 7.5 5.3 26.3 35.4 33.3
AR339 (HRsp variant) 6.4 6.4 6.4 6.7 6.2 6.2 6.5 7.8 10.0 7.5 26.1 34.3 32.4
Girdwood S.A. 3.3 3.3 3.6 3.6 3.1 3.1 5.0 6.7 4.4 2.2 26.8 36.3 34.1
S.A.AR86 6.9 6.9 6.9 7.1 6.7 6.7 6.5 8.9 6.2 3.5 28.3 37.2 34.4
YN87448 3.6 3.6 3.8 3.8 3.3 3.3 5.0 6.2 2.6 5.5 26.2 35.7 33.4
XJ-160 19.5 19.7 19.5 19.7 19.5 19.5 19.6 18.5 19.7 18.8 19.3 31.8 32.6
MRE16 28.3 28.5 28.3 28.5 28.3 28.3 28.5 27.4 28.0 27.7 27.9 23.6 32.6
SW6562 27.3 27.6 27.3 27.6 27.3 27.3 27.0 26.9 27.6 24.9 27.1 25.2 27.4
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SINV antibodies in resident grouse (Tetraonidae) in Finland (V)
In  a  previous  study,  SINV  antibodies  were  found  from  24/80  of  game  birds  and
7/41 of mammals in Ilomantsi, Eastern Finland in 1981-1983 [31]. We collected 340
blood  samples  from  resident  grouse  by  hunters  between  10  September  and  31
October 2003, and 281 samples between 10 September and 31 October 2004 (V:
Table 1, Fig. 1D). In 2003, one year after the human outbreak, the total prevalence
of SINV HI antibodies in the grouse was 27.4%, but fell down to 1.4% in 2004 (V:
Table 1). The difference was statistically significant ( 2 = 76.8, p<0.001).
The data indicate that grouse become exposed to SINV, and the virus could have
an  endemic  cycle  involving  grouse.  It  remains  unclear  whether  SINV  can  be
pathogenic to grouse. Detection of high antibody titers in the grouse in 2003
implies that the birds have almost certainly been infected and produced a
significant viremia. In 2003, the prevalence was very high in North Karelia (44%),
Western Finland (Southern Ostrobothnia, Vaasa, and Central Ostrobothnia) (44%),
and Central Finland (41%), but pronounced also in Lapland in Northern Finland
(18%) (V: Fig. 1D) (Figure 8).
In 2003, 32.0% of the juveniles (born the same year) and 23.3% of the adults were
seropositive,  and  in  2004,  none  of  the  juveniles  and  2.9%  of  the  adults  were
seropositive (96/621 of the grouse were of unknown age). As one third of the
juvenile grouse were seropositive in 2003, it is likely that active transmission of the
virus to the grouse population took place that year. In addition, a large proportion
of  these  grouse  showed  a  markedly  high  antibody  titer.  Capercaillie  and  Black
Grouse showed the highest seroprevalence, both 31.3%; the rates for Hazel Grouse
and Willow Grouse were 22.4% and 20.0%, respectively. The serological methods
(HI  and  NT)  that  were  used  in  this  study  are  stringent  and  can  only  detect
relatively potent antibody responses; the true seroprevalence of the birds may
have been higher than reported here. In conclusion, resident grouse showed high
seroprevalence  of  SINV  one  year  after  a  human  outbreak  in  Finland,  and  thus
grouse might contribute to the human epidemiology of SINV. They could possibly
act as amplifying hosts for SINV; however, longitudinal studies, and detection of
the virus in grouse are needed to establish their role.
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Figure 8.
Map of Finland and the hospital district division.
SINV antibodies in migratory birds during spring migration (V)
In  a  previous  study,  no  neutralizing  antibodies  were  found  in  the  few  hundred
arriving  migratory  birds  that  were  studied  on  the  Swedish  coast  in  1983;  from
nesting birds (both residents and migrants), the antibody prevalence was 3.4% in
July,  and 10% in August  of  the same year  [88].  In  the UK,  SINV antibodies  have
also been demonstrated in resident and migrant birds and poultry [32]. In Swedish
passerine  birds  sampled  in  mid-summer  during  the  1990s  (i.e.  not  during  the
spring migration), fieldfare (43.3%), redwing (37.0%), and song thrush (22.2%)
each had a significantly higher SINV-antibody prevalence than the average (7.7%)
of all species studied [153]. The prevalence was significantly higher in birds
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sampled after the hatching year (13.9%), compared to the ones sampled during the
hatching year (2.4%).
Prior  to  the  present  study,  SINV  antibodies  had  not  been  detected  in  migratory
birds during their spring migration to Northern Europe. We collected 836 blood
samples from migratory birds, of which 806 during spring migration in May 2004
and  in  May  2005  in  Finland.  SINV  HI  antibodies  were  detected  in  three
individuals during spring migration: a robin (Erithacus rubecula) and a song thrush
(Turdus philomelos)  from  Tauvo  in  2004,  and  a  red-backed  shrike  (Lanius collurio)
from Lågskär in 2005 (V: Fig. 1A, Table 2). The song thrush was born the previous
year; the age of the other two positive birds remained unknown. SINV RNA could
not  be  detected  with  RT-PCR  from  these  birds,  and  neither  was  virus  isolation
successful  from the available  whole  blood samples  of  the seropositive  robin and
song thrush. This could be due to that detectable viremia had already passed, and
studying seronegative birds instead could be worthwhile in the future. However,
the low seroprevalence suggests that viable SINV in arriving migrants could be a
rare event.
Robin and song thrush mainly winter in Western Europe (some individuals
migrate to North-Western Africa), and red-backed shrike, instead, overwinters in
eastern tropical and southern Africa [54]. Although the samples were collected in
areas,  which  are  usually  the  first  landing  areas  for  the  birds  when  they  arrive
overseas, virus infection during the previous year in Northern Europe cannot be
excluded. In conclusion, SINV-seropositive migratory birds arrive in Northern
Europe during spring migration. However, detection of viable SINV in migratory
birds remains to be shown, and would be the ultimate proof for their involvement
in distributing SINV.
INCIDENCE AND SEROPREVALENCE OF SINV IN HUMAN POPULATION IN
FINLAND (V)
We  studied  recent  human  epidemiology  of  SINV  in  Finland.  A  total  of  2529
specimens submitted to the Helsinki University Central Hospital Laboratory
during 1999-2003 were tested for SINV IgG-antibodies (IgM-positive samples were
excluded).  Standardized  to  the  age  distribution  of  the  Finnish  population,  the
estimated seroprevalence was 5.2% (V: Fig. 2). Brummer-Korvenkontio et al. have
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previously reported that the seroprevalence of SINV in the Finnish population
rose considerably from 1981 to  1995,  and the seroprevalence in  pregnant  women
in 1992 was 0.6% [31]; in our study, the seroprevalence in 20-39-year-old women
was 2.3%, further suggesting a continuous increase in the seroprevalence of SINV
in Finland.
In our material, seroprevalence in men was significantly ( 2 = 4,721, p<0.030)
higher than in women and the seroprevalence increased with age (V: Fig. 2), while
the incidence rates for women were higher than for men. This unexpected finding
might be explained by the possibility that infected men are more frequently
asymptomatic than women, but more investigations are clearly required.  The
seroprevalence was high in Eastern Finland, especially in North Karelia and
Kainuu, but also in Central Ostrobothnia in Western Finland (V:  Fig. 1B) (Figure
8).  Two previous studies in Sweden have reported that the most endemic area of
SINV  infections  is  between  the  60th and 63rd parallels [76,155], corresponding to
central Finland.
The SINV seroprevalence in 1850 hospital patients in Finland studied by Laine et
al., was 19% in individuals aged below 10 years [134]. Our results are in
contradiction to this, as only 1.4% of the individuals aged 0-9 years were
seropositive, and the seroprevalence increased gradually by age. In the age group
60-69 years 15% of the population had immunity to SINV. Considering the high
infection rate, and that the infection may cause prolonged joint symptoms (III, IV)
[133,182,239], the disease is a potential public health concern.
The incidence of SINV during epidemic years was 25.6/100,000/year in 1995 and
11.5/100,000/year in 2002 (V: Fig. 3); the average annualized incidence in the non-
epidemic years (1996-2001 and 2003) was 2.4/100,000/year. In the study of
Brummer-Korvenkontio et al., the incidence in almost 10,000 Pogosta disease
suspected individuals during 1980-1996 was 2.7/100,000 in Finland, being highest
in the province of North Karelia and Central Finland [31]. In our study, rates were
highest in North Karelia (25.7/100,000) (V:  Fig. 1C); the incidence peaked in both
North Karelia and Southern Ostrobothnia during the 1995 and 2002 outbreaks (V:
Fig. 3). However, one year after the outbreak in 2003, the rates were twice as high
in  Southern  Ostrobothnia  compared  with  North  Karelia  (V: Fig. 3), possibly
reflecting the high population immunity towards SINV in North Karelia after the
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2002 outbreak. The high seroprevalence in Kainuu with a very low incidence
could be due to considerable underdiagnosis.
Several unsolved questions still remain in the peculiar epidemiology of SINV in
Northern Europe. In addition to birds, the seven-year cycle could involve other
vertebrates,  as  well.  On the other  hand,  the virus  might  not  require  a  vertebrate
host at all; it could be maintained through winter in transovarial mosquito
transmission. Under experimental conditions, CHIKV is transmitted transovarially
[265]; studies on SINV are not available. The limited time frame of clinical SINV
infections  in  August  and  September  is  presumed  to  be  due  to  that  strictly  late
summer mosquito species function as vectors for the virus. A previous study
suggests that the depth of snow cover in the late winter could predict the number
of Pogosta disease cases [31]. Culex and Culiseta mosquito species spend early
summer  as  larvae  in  aquatic  milieu  [27],  which  dry  too  soon,  if  the  preceding
winter  has  been  poor  with  snow.  This  supports  the  idea  that Culex and Culiseta
mosquitoes, abundant in late summer, are important vectors for the virus.




Alphaviruses  are  found  throughout  the  world,  and  some  of  them  are  causative
agents of severe clinical diseases. Neuropathogenic alphaviruses are both equine
and human pathogens, and their epidemiology, pathogenesis, and clinical course
have been studied in detail. Despite the currently multifold incidence compared to
encephalitic alphaviruses, research on alphavirus arthritides has been less active.
This dissertation summarizes our studies on the etiology, clinical and laboratory
manifestations, laboratory diagnosis, and epidemiology of SINV infection in
Finland.
This study showed that SINV strains, closely related to other Nothern European
strains and South-African strains, are the etiological agents of Pogosta disease.
Our  data  suggest  that  resident  grouse  may  be  involved  in  the  epidemiology  of
Pogosta disease, and migratory birds in distributing the virus over long distances.
Despite  the  seven-year  cycle  in  the  Pogosta  disease  epidemiology  remains  a
mystery  for  the  time  being,  the  results  warrant  further  investigations  on  birds.
Longitudinal  studies  on  resident  grouse,  and  detection  of  viable  virus  in
migratory birds would be required to establish their role.
We showed that after the acute SINV infection prolonged joint manifestations
occur in a considerable proportion of patients, which may have public health
implications, especially in the highly endemic areas. It can be estimated that solely
in  the  province  of  North  Karelia,  where  the  seroprevalence  is  10%,  several
hundred patients manifest with chronic arthritis, and a few thousand people with
arthralgia as sequelae of previous SINV infection. SINV infection should be
considered in the differential diagnosis of undefined, persistent joint symptoms.
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Currently,  the  pathogenesis  of  the  alphavirus  arthropathy  is  poorly  understood.
Understanding the pathogenesis would be crucial for possible development of
specific  treatment  or  prevention  for  the  infection,  and  therefore  remains  an
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